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Abstract 
The existing technique for the use of stem cell based therapies for joint repair are 
based on time-consuming laboratory culture expansion protocols that are also 
expensive.  The purpose of this thesis was to devise ways to exploit the discovery of 
synovial fluid mesenchymal stromal cells (MSC) towards the cost effective 
development of one stage cellular therapy development for knee osteoarthritis 
(OA).  This work is based on the hypothesis that synovial fluid (SF) MSC that originate 
from the synovium, can be greatly increased in the joint cavity using a novel device. 
Secondly, it was hypothesised that knowledge of the joint in vivo environment following 
a microfracture procedure could be used to facilitate MSC adherence to, and migration 
towards a biological scaffold, similar to a microfracture, as a first step towards novel 
cartilage regeneration therapy development.   First, a MSC releasing device was 
developed for effective cell release and minimal entrapment within the device. 
Secondly, using biological scaffolds, in an in vitro model, MSC were capable of 
adhering to, and migrating toward the scaffold, and that the scaffold composition could 
play an important function on migration. Finally it was shown that standard joint 
arthroscopy, washes resident joint fluid MSC away. It was then demonstrated in the 
laboratory that synovial brushing does indeed release cells that have the MSC 
immunophentype (CD73, CD90, CD105) following culture expansion.  In addition, 
released MSC demonstrated good chondrogenic, adipogenic and osteogenic 
potentials, further endorsing their use for articular cartilage repair. A prototype device 
was tested in humans and was shown to significantly increase fluid MSC in vivo in 
man. The thesis findings, demonstrate MSC augmentation, which provides the basis of 
testing novel regenerative strategies, from bench to operating theatre in orthopaedics, 
and supports the objective of a one stage cost effective procedure for joint repair.  
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Chapter 1	  
1. Introduction 
  An introduction to the Knee Joint 1.1
The knee is a complex joint, comprising of bone, soft tissue and a neurovascular 
supply. It is the largest joint in the human body, consisting of articular surfaces 
between its three bones (femur, tibia and patella), two menisci and a number of large 
ligaments including the cruciates. The knee joint belongs to a family of joints known 
collectively as synovial joints, of which the knee is classed as a condyloid type (Moore 
et al, 2015).  The hyaline cartilage aids in a smooth, painless joint movement. The 
knee joint synovium is involved in a variety of functions including lubrication and 
nutrient exchange (Moore et al, 2015) (see Figure 1).  
 
 
Figure 1: The knee joint. Diagram of the knee joint, including bone, and soft tissue 
components (original diagram adapted from: www.slideshare.net). 
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 An introduction to the knee joint synovium 1.2
The synovium is a membranous connective tissue, lining the inner surface of the joint 
capsule. It comprises of lymphatics, nerve and blood vessels supply. The membrane is 
divided into two layers; the inner layer, known as the intima, and the outer layer know 
as the sub-intima (Stacey et al, 2007) (see Figure 2). 
 
 
 
 
Figure 2. Normal synovium. Intima and sub-intimal layers, Image adapted from Stacy 
et al, 2007. 
 
The sub-intimal region contains the blood and lymphatic supply of the membrane, 
which are involved in nutrition of joint structures such as the cartilage. Both layers of 
the synovial membrane act collectively to create a sealed system, this structure keeps 
the synovial fluid closed within the capsule, thus allowing for nutrient exchange. In 
addition, this system also allows for large compressive forces to be dissipated (Smith 
et al, 2011). Of particular relevance is that the synovium and the articular cartilages are 
embryologically derived from the same limb bud joint interzone region (Koyama et al, 
2008).   The knee joint synovium is particularly large due to the large suprapatellar 
pouch recess, which will be shown later in this thesis to be key to novel therapy 
development for stem cell based repair.    
 
 
 
 
In#ma&
Sub*in#ma&
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 An introduction to synovial fluid (SF) 1.3
The ultrafiltration of blood plasma, coupled with hyaluronin, glycoproteins, lubricin, 
proteinases and collagenases contribute to creating SF. The unique composition of SF 
creates an environment where the SF viscosity contributes resistance against shear 
and compressive forces, in addition to providing vital lubrication of the joint lining, and 
nutrients and a supply of oxygen to important structures such as the cartilage (Blewis 
et al, 2007).    
 An introduction to cartilage 1.4
Cartilage is the connective tissue that plays a vital role within the body especially in 
stress resistance at the ends of bones: within a healthy knee the cartilage layer can 
range between 3-4mm in thickness. There are three types of cartilage, hyaline, fibro 
and elastic cartilage.  Hyaline cartilage is the type that is found on the terminal ends of 
long bones within the joint cavity. Its structure allows it to provide resistance to 
compression and shear forces. Chondrocytes secrete the extracellular matrix, which 
consist of aggrecan or proteoglycan, which attract large volumes of water. The 
extracellular matrix also consists of collagen fibres that provide the tensile strength. As 
the chondrocyte produces the extracellular matrix, they themselves become engulfed 
within it. At this phase the fully matured chondrocytes develop and entrapped within a 
pit known as a lacunae (see Figure 3). 	   
 
 
 
 
 
    
 
 
 
 
 
 
Figure 3: Histology of a hyaline cartilage 1. Section of hyaline cartilage, showing a 
chondrocytes, entrapped within a lacunae pit (original image adapted from 
www.pinterest.com) 
Chondrocyte+
Lacunae+
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Depending on the combination of key components such as, collagen, elastin fibres and 
proteoglycan, the type of cartilage present is determined. Within the knee, articular 
surfaces, hyaline cartilage is present; however, in the knee other types of cartilage are 
also resident, in structures such as the medical and lateral meniscus, where 
fibrocartilage predominates. The growth of hyaline cartilage is unique, as it is an 
avascular structure, and, thus, regeneration involves diffusional processes (Buckwalter 
et al, 2005). Indeed, growth of hyaline cartilage has been described in two differing 
ways: 1) interstitial growth in which chondrocytes divide and produce more extracellular 
matrix, and 2) appositional growth, where chondrocytes produce new layers of matrix 
from the top down (Hayes et al, 2001). This combination of growth provides hyaline 
cartilage with a layered structure, separated into zones. Articular hyaline cartilage 
comprises four zones; superficial, transitional, deep and the calcified zones, which are 
placed on top of the subchondral bone region (see Figure 4). 
 
Figure 4: Histology of a hyaline cartilage 2. Four zones of hyaline articular cartilage; 
superficial, transitional, deep and the calcified zones, placed on top of the subchondral 
bone region. (original image adapted from clinialgate.com) 
 
The superficial zone consists of two sub-layers, the upper layer has fibrilar sheet of 
collagen fibrils, and polysaccharide deposits, and the lower layer is the cellular layer, 
comprising of flattened chondrocyte cells. The superficial layer is the thinnest layer of 
the cartilage: however, due to its relative high concentration of collagen, it provides the 
ability to maintain smooth gliding of opposing terminal bone ends when a shear force is 
applied, this layer is vulnerable to changes with age (Gupta et al, 2006). The 
transitional layer contains mainly proteoglycans and some round chondrocytes. This 
Transi'onal*Zone**
Superﬁcial*Zone**
Deep*Zone**
Calciﬁed*Zone**
Subchondral*bone*
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unique combination allows this layer to transition from shearing forces to compressive 
forces. 
The largest layer of the articular cartilage is the deep layer, which is key in handling 
compressive forces, and this layer sits perpendicular to the subchondral plate, which 
contains the calcified cartilage layer. This region contains the tidemark layer, which is 
the actual boundary between cartilage and bone. The deep non-articular layer is the 
location where hyaline cartilage calcifies when it matures (Fox et al, 2009). 
 
Due to the limitation of the knee joint blood supply, coupled with the avascular nature 
of cartilage, repair of injuries to the articular cartilage may be challenging, compared to 
other soft tissue structures. Injury or minor disruption to the homeostasis between the 
articular surface, synovium and synovial fluid, and other soft tissues (i.e. meniscus) 
may trigger a chain of events leading to the condition known as osteoarthritis (OA). 
Historically it was thought that articular cartilage was not capable of joint repair 
(Grande et al, 2013). Nevertheless, despite the apparent lack of vascularity there is 
increasing evidence from experimental and clinical settings that knee joint cartilage 
repair occurs (Koshino 2003; Grande 2013). 
 An introduction to osteoarthritis   1.5
Osteoarthritis (OA) from a pathophysiological perspective is a degenerative joint 
disease (Goldring et al, 2010). OA is a common condition in the UK, and up to 8.75 
million people were treated for this condition in 2015, of which more than 50% are 
related to knee OA. OA is recognised to be a disease of the elderly population, mainly 
affecting people from 60+ years old. Currently 164,000 knee and hip replacements are 
undertaken in the UK per year, at the point when the disease is at its most destructive, 
costing the National Health Service (NHS) in the region of £1 billion (Arthritis Research 
UK). This disease is not limited to just the physical symptoms of pain for individuals, it 
also can play a role in the disruption of patients’ psychosocial state, (Wise et al, 2010) 
which can increase the burden to the health service. 
Early knee OA can be triggered from many causes; however, the main trigger is 
thought to be an injury causing an isolated condylar injury to one of the articular 
components of the knee, such as cartilage, meniscus, anterior or posterior cruciate 
ligaments or an intrarticular fracture (McKinley T, Giannoudis P, et al. 2010). These 
types of injury lead to a process of destruction and inflammation, which ultimately leads 
to end-stage OA. Aside from pain during a severe traumatic injury, initial symptoms of 
 -­‐16-­‐	  
knee OA, may present as stiffness, which gradually leads to pain. Pain intensity will 
gradually escalate, due to mechanical load imbalance, as the patient’s gait is altered, 
known as an antalgic gait. As the disease progresses, subchondral inflammation 
occurs which leads to the development of subchondral cysts, common in advanced 
end-stage OA (Roemer et al, 2009). Indeed, end-stage OA is marked by abrasion of 
the cartilage. Joint effusion and subchondral bone bruising may arise, which lead to 
further pain and ongoing joint damage (van Dijk et al, 2010). Coupled with an 
increased life expectancy in Western populations, OA represents a growing healthcare 
burden (van Dijk et al, 2010; Adatia et al, 2012; Chen et al, 2012; Barry et al, 2013). 
Clinically, knee OA is classified using radiological visual grading, known as the 
Kellgren-Lawrence scale that was first proposed in 1957. There are 5 grades, from 0 = 
no radiographic features of OA, to 4 = extensive OA, comprising of osteophytes, 
marked joint space narrowing, and severe sclerosis (Emrani et al, 2008). Whilst joint 
replacement surgery is effective for established OA there is a lack of therapies 
available to combat early stages of the disease. 
 
 Current treatment options for early and advanced knee osteoarthritis 1.6
The table below outlines a generalized view of OA progression, using the Kellgren-
Lawrence grading system combined with current treatments available, treatment option 
may vary according to local NHS protocols.  
   
Table 1: An overview of current treatment options for OA 
 
Initially patients are treated with oral analgesia, including paracetamol and codeine or 
non-steroidal anti-inflammatory drugs. Collectively, these strategies may alleviate pain 
but make no difference to the underlying disease process. Analgesia coupled with 
physiotherapy for quadriceps muscle strengthening and sensible weight loss, help 
Simple Analgesia 
Grade&0& Grade&1& Grade&2& Grade&3& Grade&4&
No treatment 
Intra-articular corticosteroid injection 
Osteotomies  
or  
Partial Knee replacements  
Total Knee Replacements  
Arthroscopy-lavage and debridement  
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retain joint mobility, and may allow the patient to maintain good quality of life, this can 
lead to a delay in the progression of the disease. Intra-articular corticosteroid injections 
have also played a useful role, by controlling the initial inflammatory process, with 
patients showing transient improvement in function (Bellamy et al, 2005). Arthroscopic 
lavage and debridement is a minimally invasive surgical procedure to visualise the 
knee cavity to remove inflamed and damaged tissue; however, there is no long term 
benefit, as patients inevitably develop OA (Acebes et al, 2009; Rodriguez-Merchan et 
al, 2010; Thorlund et al, 2015). 
 Surgical techniques for joint regeneration 1.7
When patients present with isolated condylar injuries, a surgeon can use procedures 
such as microfracture, autologous chondrocyte implantation (ACI), osteochondral 
autograft transplantation/transfer system (OATS) and osteochondral allograft 
transplantation (OCA), in an attempt to restore and repair cartilage defects. 
Microfracture is a technique that was developed in the early 1990’s, by Steadman 
(Steadman et al, 1999; Steadman et al, 2002; Mithoefer et al, 2009). It is an 
intermediate minimally invasive surgical technique for professional athletes with small 
(usually less than 2 cm) lesions within the femoral condyles. During knee arthroscopy, 
the surgeon identifies the lesion within the cartilage, and once the lesion has been 
debrided, the surgeon uses an awl to create small holes down to the subchondral bone 
and this is associated with subsequent repair tissue formation. It was considered for 
many years that this allowed blood and bone marrow mesenchymal stromal cells (BM 
MSC), that have cartilage repair potential, to migrate into the lesion (Neumann et al, 
2008). The cartilage regeneration during microfracture is invariably fibrocartilage rather 
than articular cartilage. Patients that have undergone microfracture usually return 
within two years with pain recurrence. This is usually due to the fibrocartilage 
degeneration, in addition to delamination of the surrounding cartilage (Mithoefer et al, 
2009) (see Figure 5). 
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Figure 5: Microfracture. Steps in creating a microfracture. (A) Debridement of edges 
to the cavity. (B) Removal of unwanted cartilage layer. (C) Penetrating the subchondral 
bone, to create microfractures. (D) Filling of blood creating a clot (with BM MSC) which 
eventually become fibrocartilage (Mithoefer et al, 2009; Makris et al, 2014). 
 
Brittberg and Peterson first introduced ACI in 1987 for treating high-level athletes (Viste 
et al, 2012), it provides an expensive alternative to microfracture, and is not currently 
available as a treatment option within the NHS. It involves a two-step surgical 
procedure where a sample of normal hyaline cartilage, approximately 200-300 mg in 
weight, is removed from a non-weight bearing region; chondrocytes are isolated and 
expanded over a period of up to six weeks within the laboratory, following which a 
second surgical procedure to re-implant the chondrocytes is performed. Studies 
comparing ACI and microfracture show that there is little benefit in undergoing ACI 
compared to microfracture (Knutsen et al, 2007). 
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Second generation ACI have been developed, where chondrocytes harvested from 
non-weight bearing regions of the knee (via arthroscopy) are loaded and cultured onto 
a three-dimensional biocompatible scaffold, commonly referred to as a matrix-induced 
autologous chondrocyte implantation (MACI) (Jacobi et al, 2011). These are used for 
larger technically difficult defects. 
The OATS procedure replaces small defects that would not be suitable for 
microfracture, with healthy cartilage from a non-weight bearing surface region of the 
patients’ knee (from the same knee). In larger cartilage defects, or when there are 
previous failed attempts at either microfracture, ACI or OATS, then OCA can be used 
successfully (Gracitelli et al, 2015). Donor articular surface from a cadaveric source is 
used. During the procedure the surgeon will use arthroscopy to visualise and remove 
damaged articular tissue, followed by insertion of a section of donor articular cartilage, 
including a section of the underlying bone, as this allows for anchorage of the "plug” 
replacement tissue to the recipients defect. This technique is useful to fill defects that 
are moderately sized, usually more than 2cm diameter, and has the benefit of no graft 
site morbidity; however, cadaveric sources grafts, in themselves, also have limitations. 
Complications can range from simple tissue mismatching to more serious implications, 
such as disease transmission, and tissue integration complications, thus leading to 
tissue rejection (Torrie et al, 2015). Most patients that undergo arthroscopy will, at 
some point, require further surgery in the form of knee osteotomy and eventually a total 
knee replacement (TKR). 
 Non cellular based treatments for OA 1.8
For advanced OA of the knee, osteotomy is a technique that aims to realign arthritic 
damage by changing the patient’s axial load in the joint. In essence, it is a technique 
that involves removal of a "wedge’ shaped section of bone from beneath the 
compartment of the knee that is not effected by cartilage damage, known frequently as 
a "high tibial osteotomy”. In the majority of cases the osteotomy section is removed 
from the lateral side of the knee, in order to redistribute the axial load of the individual 
on to the medial compartment of the knee that usually has unhealthy cartilage. Survival 
rate for this procedure are 95% for 5 years and 79% for 10 years, demonstrating good 
patient satisfaction. The overall effect is to reduce pain within the knee of the individual 
thus delaying the time for the patient to undergo a TKR (Koshino et al, 2010; Hui et al, 
2011), (see Figure 6). 
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Figure 6: Knee osteotomy. Right knee medial compartment osteotomy. (Original 
image adapted from amirqureshi.co.uk/osteotomy) 
 
Inevitably most patients progress to end-stage knee OA, where total knee replacement 
(TKR) is necessary. The numbers of TKR has surpassed that of total hip replacements, 
and is now the leading joint replacement surgery taking place in the UK (Birrell et a/, 
2011). It involves the surgical removal of the arthritic regions (commonly medial 
compartment in a partial knee replacement, and both medial and lateral compartments 
in a total knee replacement) and replaced with a metallic-on-plastic prosthesis. Total 
knee replacement implants have a 10 year survival of 93.8% and 20 year survival of 
70.9% (Bae et al, 2012) Figure 7. Patients between 40-60 years old have poor results 
with treatments such as total knee replacement (section 1.6), as the prosthetic failure 
rate is high, meaning revision arthroplasty is required (Julin et al, 2010) 
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Figure 7: Total knee replacement. (A) Total knee replacement is a replaced with a 
metallic on plastic prosthesis. (image adapted from www.limbreconstructions.com) (B) 
Plain radiography of a left TKR (image adapted from www.hipandkneeadvice.com). 
 
  Emerging treatment options for repair of cartilage defects 1.9
As seen above, early treatment options, such as microfracture, ACI, OATS, and OCA 
provide useful, though limited outcomes when attempting to repair isolated cartilage 
injuries. For example microfracture is a relatively convenient procedure, one that allows 
repair of the defect; however, the repair tissue consists of fibrocartilage (not the normal 
hyaline cartilage), coupled with multidirectional mechanical forces, this tissue usually 
wears away quickly, lasting as little as 2 years (Mithoefer et al, 2009). With low number 
of chondrocytes at the native cartilage site, it is not possible to obtain sufficient 
numbers of these cells to effectively fill the defect, thus ACI is used as a chondrocyte 
expansion procedure. However, it remains a costly two-step surgical process, and 
therefore is not used as a treatment option within the NHS. The challenge for 
researchers is to develop a procedure that amplifies the number of chondrogenic 
potent cells, within the knee, that are capable of repairing injured cartilage sites. 
Current approaches aim to increase number of cells that have the ability to promote 
chondrogenesis, such as MSC. 
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 Mesenchymal Stromal Cells (MSC) and their potential role within an injured 1.10
arthritic knee joint 
Mesenchymal Stromal Cells (MSC) are capable of differentiating into chondrocytes, 
thus play a vital role in cartilage regeneration (Pountos et al, 2006; English et al, 2007; 
Koga et al, 2009; Nakamura et al, 2012; Anderson et al, 2014). Although originally 
thought to be bone marrow resident cells, MSC have now been documented to reside 
within multiple regions within the body, including the knee (Segawa et al, 2009; Via et 
al, 2012; Candela et al, 2014). These cells belong to the family of stem cells, which are 
defined by their ability to self-renew and differentiate into different cell types (Watt et al, 
2000). MSC are somatic (or adult) stem cells, as opposed to embryonic stem cells that 
are totipotent (have the ability to differentiate into all cells types within an organism) 
whilst somatic MSC are multipotential (have a restrictive differentiated capabilities) 
(Lee et al, 2006). 
The research history of MSC began with Friedenstein’s (1976) (Friedenstein et al, 
1976) original identification of bone marrow (BM) cells that formed fibroblastic colony 
forming units (CFU-Fs), they also displayed multipotency. Culture expanded daughter 
progeny of such cells have been termed mesenchymal stromal cells, mesenchymal 
stem cells, marrow stromal cells or multipotential stromal cells (MSC) have been 
studied in depth over the past few decades, and at each stage more of them have 
been discovered in multiple regions of body including, peripheral blood, umbilical cord 
cardiac tissue (Barry et al, 2004), adipose tissue (Zuk et al, 2002), trabecular bone 
(Tuli et al, 2003), synovium and periosteum (De Bari et al, 2001; De Bari et al, 2008), 
and synovial fluid (Jones et al, 2004). MSC have the ability to differentiate into 
mesodermal linages such as osteoblasts, adipocytes, and importantly for cartilage 
regeneration, chondrocytes (Barry et al, 2013). Along with their differentiation 
properties, MSC also possess the ability to express cytokines such as Transforming 
Growth Factor beta (TGFp), Vascular Endothelial Growth Factor (VEGF), and 
Epidermal Growth Factor (EGF), that are involved in stimulating tissue repair, making 
MSC a useful tool in combating knee arthritic injures. So how are MSC characterized 
and how are they sourced for use within such injuries? 
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 MSC definition and characterization  1.11
MSC (Figure 8) in vitro are defined by three main characteristics:  plastic adherence, in 
vitro differentiation into multi-lineages (osteoblasts, chondrocytes and adipocytes) and 
cell surface markers (CD73, CD90 and CD105) and the absence of other cell markers 
(CD11b or CD14, CD19 or CD79a, CD34, CD45 and HLA-DR) (Lv et al, 2014). Colony 
forming unit-fibroblasts (CFU-F) assays are used in the enumeration of MSC as a tool 
for quantifying the frequencies of MSC (Jones et al, 2002;  Jones et al, 2004). The 
international Society of Cellular Therapy (ISCT) recommend that MSC express ≥ 95% 
of CD73, CD90, CD105 markers, and ≤ 2% of CD11b or CD14, CD19 or CD79a, 
CD34, CD45 and HLA-DR (Dominici et al, 2006). Mesenchymal stromal cells possess 
a great capacity for self-renewal, in terms of clonogenicity, and are capable of 
maintaining their multipotency. However, their ability to proliferate and differenate 
decreases with age (Wang et al, 2014). CFU-Fs is a method used for quantifying MSC 
in cell preparations (Pochampally et al, 2008) in which MSC are plated on to culture 
plates, and adhere within 24 hours. Within a few days cells begin to multiply and form 
colonies, that latter can be used as a quantification tool.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Mesenchymal Stromal Cells. Characteristic fibroblast-like morphology of 
synovial MSC (stained in methylene blue) at x20 magnification  
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 Sources of MSC for repair of articular defects or OA 1.12
As previously mentioned, MSC have been identified in multiple regions of the body; 
however, a reliable source of MSC that can be used for regenerative purposes has 
been difficult to establish. Bone marrow MSC (BM MSC) have been extensively 
researched as a potential source of MSC to fill cartilage defects and aid in repair, and, 
indeed, as mentioned above, microfracture utilises the BM MSC that trickle through 
into the cartilage defect to repair into fibrocartilage. However, the number of BM MSC 
aspirates is low, and typical yields of BM MSC from a bone marrow aspirates are in the 
region of 0.001-0.002% (Peng et al, 2008). Higher numbers of BM MSC are potentially 
available; however, they require release by means of digestion by using enzymes such 
as collagenase (Jones et al, 2010). In such cases, BM MSC need to be expanded in 
vitro for regular use, by means of amplification, which usually can take up to 3 weeks. 
Currently this method of augmentation is useful in combating the issue of relatively low 
harvest of endogenous MSC; however, MSC do gradually lose progenitor properties 
(Banfi et al, 2000) resulting in impaired cell function as part of the senescence pathway 
(DiGirolamo et al, 1999). Another source of MSC, with a more impressive yield, is 
adipose-MSC (AD MSC), which boast harvests of up to 7% (Kern et al, 2006). The AD 
MSC appear to be an attractive source of MSC; however, the gain in encouraging cell 
numbers, may have associated unfavourable outcomes also, especially when needed 
to repair cartilage defects, as shown by Peng et al. (2008). They showed that 
chondrogenic abilities of both BM MSC and AD MSC are inferior to cartilage-MSC. 
Umbilical cord MSC (UC MSC) do offer an alternative source of cells, to be utilised for 
regenerative purposes, due to their rather attractive proliferation and differentiation 
capacities, (Baksh et al, 2007), which make them an appealing allogeneic cell type to 
use. However, coupled with ethical constraints, these cells lack incentives for local 
health care providers. Injecting MSC into defect sites is in its infancy, have only being 
investigated within the research setting thus far, and has no treatment option available 
within the NHS. Applications used for cartilage defects have been researched, using 
either BM MSC or peripheral blood MSC (PB MSC), both of which were supplemented 
with hyaluronic acid (a major constituent of synovial fluid found within the knee). In two 
separate studies, following microfracture, patients were injected with culture expanded 
MSC from either BM or PB (Lee et al, 2012; Saw et al, 2013); in a clinical setting, the 2 
year follow-up results demonstrate positive outcomes with decreasing patient pain 
scores, and better repair visualised using MRI imaging. Injection of MSC in an OA knee 
is also being investigated, using either BM MSC or AD MSC. During a routine 
arthroscopic procedure in two studies, culture expanded BM MSC were injected into 
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the joint, and 0.5-1 year follow-ups indicated improvements in patient knee pain scores 
(Centeno et al, 2008; Orozco et al, 2013). Similar results, of improvement in pain 
scores, such as the Western Ontario and McMaster University Osteoarthritis Index 
(WOMAC) were achieved, when the authors used culture expanded AD MSC, 
supplemented with PRP that was injected into an OA knee following arthroscopic 
debridement (Koh et al, 2012; Koh et al, 2013; Filardo et al, 2015; Ornetti et al, 2016). 
Autologous MSC are an appealing source of MSC cells due to their differentiation 
capacities; however, the consistently low yields of cells, the necessity to culture expand 
cells, coupled with a surgical revisit to the site of injury, will ultimately present obstacles 
towards a successful low cost, one step repair of cartilage defects. This emphasises 
the need for a technique that provides good yields of autologous MSC that are cost 
effective, and uses only minimal surgical interventions, and are easily accessible by the 
surgeon. One potential region of the body where a source of autologous MSC can be 
located is the knee itself. As discussed previously, BM MSC percolate into a 
microfracture site and repair tissue as fibrocartilage. However, the numbers of cells are 
low, and, thus, other sources of MSC within the knee are required. Indeed, the knee 
exhibits multiple sites of endogenous MSC in the form of synovial fluid MSC (SF MSC), 
synovial MSC (SY MSC) and intrapatellar fat pad MSC (IFP MSC). SF MSC, 
phenotypically, are similar to BM MSC (Jones et al, 2008; Sekiya et al, 2012), and 
demonstrate better chondrogenic capabilities, compared to BM MSC. A further 
advantage of SF MSC is the greater number of cells present in arthritic knees, 
compared to non-arthritic knees (Jones et al, 2004). Another source of endogenous 
autologous MSC, are SY MSC (De Bari et al, 2001). Comparable to SF MSC (Baboolal 
et al, 2014), SY MSC demonstrate chondrogenic abilities, and express better 
chondrogenic potentials than BM MSC and IFP MSC (Sakaguchi et al, 2005; Fan et al, 
2009), and would be easily accessible by the surgeon. Cell-surface markers provide a 
useful tool in recognizing similarities between MSC type within the knee joint (Barry et 
al, 2013) expanded MSC typically express CD73, CD90 and CD105 (Figure 9); 
however, cell surface markers may differ when comparing source tissue with 
expanded, for example down-regulation of surface marker CD271 does occur following 
culture expansion (Boxall S, et al 2012) .SY MSC demonstrate promising results in 
animal models. Studies using a porcine model, involved harvesting synovium and 
digesting it in collagenase. Following culture expansion, the SY MSC were re-injected 
into the articular defect, to differentiate into chondrocytes and regenerate into cartilage 
compared to non-treated controls (Nakamura et al, 2012).  
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Figure 9: Endogenous supply of MSC within the knee joint. Characteristics, culture 
phenotypes and cell-surface markers of MSC located within the knee (Barry et al, 
2013).  	  
It is essential that future use of MSC within the injured knee meet the following 
conditions, to make it more available to patients within the NHS: 1) easy to obtain, 
ideally utilizing endogenously situated MSC; 2) minimize the need for expansion, thus 
maintaining their phonotypical identity; 3) require minimal surgical operating time and 
numbers of procedures, thus reducing mortality and morbidity rates for patients; 4) a 
process by which cells reach sites of injury for repairing; 5) cost effective process, thus 
allowing it to be available to all patients who will benefit from regenerative applications. 
In addition to augmenting cell numbers, there is a need for a process of loading MSC 
within injured sites. Growth factors (GF) are natural chemical stimulants that encourage 
articular cartilage production, and aid in cell homing. 
 Growth factor as stimulants for articular repair 1.13
Articular cartilage is regulated by an interaction between mechanical properties of a 
joint and the chemical stimulus in the form of Growth Factors (GFs). Growth factors 
such as Transforming Growth factor (TGF-β), Insulin-like Growth factors (IGFs) and 
Fibroblast Growth factor (FGF) encourage articular cartilage production. Each type of 
GF play a unique role: TGF-β: maintains chondrocytes phenotype, promotes cell 
differentiation.	  Whereas	   IGFs	  encourage	  chondrocyte	  proliferation	   (Chaipinyo et al, 
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2002), in addition, they also play a preventative role in cartilage degradation, by 
binding to proteoglycans, during periods of catabolism. To maintain the delicate 
homeostatic balance, FGF aid in cartilage suppression, by reducing synthesis of 
proteoglycan by up regulating matrix-degrading enzymes production  (Li et al, 2012; 
Ellman MB, et al. 2013) and inhibiting articular chondrocytes (Kato et al, 1990), thus 
maintaining the homeostatic balance. Research has demonstrated improvements of 
articular cartilage damage with use of such products, as PRP intra-articular injection 
(Van Pham et al, 2013; Ornetti et al, 2016). In clinical practice, an effective method of 
delivering GF within a joint is by using PRP. Enriched with a host of GF, such as TGF-
β, (Mollon et al, 2013)  simple centrifugal processing steps of patients peripheral blood, 
enables clinicians to extract this chondrogenic-promoting constituent, and inject it into 
an injured knee. Augmentation of endogenous autologous MSC for use within the 
injured knee articular surface so there is an emerging scientific rationale for 
endogenous MSC manipulation towards OA therapy development. Previous animal 
studies have demonstrated cartilage regeneration of condylar defects even without the 
introduction of transplanted MSC (Lee CH, et al 2010). A key aspect of this thesis is to 
exploit knowledge of joint resident stem cells for OA therapy. First, the synovium and 
articular cartilage share the same embryonic origin and of course the synovial cavity 
exists because of these two structures.  Secondly, the fact that a stem cell population 
resides in both the synovium and the synovial fluid, thus having ready access to 
superficial articular cartilage, leads to novel ways of thinking about joint repair. The 
superficial transitional area of cartilage has stem cells activity that has been shown in 
an animal model (Dowthwaite et al, 2004), in addition chondrocyte differentiation takes 
place from the “top down” or by so called appositional growth (Kozhemyakina, et al. 
2015). All of these factors point to the notion of how SY MSC and SF MSC might have 
a role in cartilage regeneration from superficial layers.    
 
MSC have shown to be a useful tool in the repair of cartilage, thus there is a clinical 
need for a technique that provides good yields of autologous MSC. This treatment 
would be desirable for isolated articular cartilage knee injuries, as well as for more 
advanced knee arthritic conditions such as joint osteoarthritis. As stated previously, 
one potential region of the body were a source of autologous MSC, can be located is 
the knee itself. Current clinical studies applying autologous MSC into cartilage defects 
focus on the use of BM MSC, AD MSC, with limited opportunities for use of SF or SY 
MSC as seen in a review by Vonk et al (2015). In addition Vonk states that umbilical 
cord derived MSC are the common source of allogeneic MSC used in clinical studies 
for cartilage repair. This leads to believe that there is a requirement for use of an 
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endogenous source of MSC, to fill this clinical vacuum. An endogenous supply of MSC 
can be in the form of SF MSC, and SY MSC, phenotypically are similar to BM MSC 
(Jones et al, 2008; Sekiya et al, 2012), and to each other (Baboolal et al, 2014), and 
demonstrating better chondrogenic capabilities compared to BM MSC. If a technique 
was developed in which SF MSC were supplemented with released SY MSC from the 
synovial lining to provide a good yield of autologous MSC, it would potentially lead to 
enhancing the quality of articular cartilage repair. This would have benefits for both the 
patients and the healthcare provider. This technique would also negate the need to use 
allogeneic MSC, thus helping to prevent infections.  
 Purpose made device to release SY MSC 1.14
The focus of this thesis was to develop a novel device design in an attempt to increase 
the total MSC within a joint cavity, thus potentially creating an environment that would 
favour high quality articular cartilage repair. As mention earlier, (De Bari et al, 2001) 
the synovium offers great potential in providing an abundant endogenous supply of SY 
MSC. Coupled with endogenous SF MSC, this will further aid in increasing the number 
of native MSC for repair of articular defects. Mechanically dislodging MSC from the 
synovial lining will potentially increase the number of SY MSC without the need of 
culture expansion. A purpose made device to release SY MSC, will be the ideal 
instrument to aid in the release of these cells. In addition, these released SY MSC 
coupled with resident SF MSC potentially will home towards and adhere to a 
arthroscopically created microfracture (biological scaffold), within the articular defects, 
using local chemo-attractants (such as growth factors, chemokines) released from the 
biological scaffolds (Vanden et al, 2014), thus leading to a more cost effective repair of 
an arthritic defect.   
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2. Hypotheses  
This work tested the hypothesis that synovial fluid MSC were removed inadvertently by 
existing arthroscopic surgical techniques, but their numbers could be restored by 
release of MSC from the adjacent synovium using a purpose-built device. Secondly, 
such released cells would retain MSC functionality and may migrate into sites of injury 
as determined by an in vitro clot assay model.  
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3. Aims and Objectives 
The overarching aim of this study is to use the philosophy that endogenous MSC can 
be used to regenerate articular cartilage within in the knee. The first aim was to 
augment synovial fluid with newly released MSC from the synovium. The second aim 
of this study was to explore biological scaffolds and their effect on MSC adherence and 
migration, thus providing a novel strategy for the future testing of cost effective therapy 
to treat early stages of joint degeneration in OA.  These aims were addressed using 
the following objectives: 
 Obtaining MSC from the synovium ex vivo  3.1
• To use colony forming unit - fibroblast assay (CFU-Fs) to 
enumerate MSC released from the synovium.  
• To develop a purpose made device to release SY MSC, and to 
demonstrate an increased MSC release compared to cells trapped 
in the brush with results confirmed by CFU-F assay and DNA 
analysis.  
• To demonstrate trilineage differentiation of released MSC from 
synovial tissue following culture expansion.  
 Adhesion and migration of MSC with a biological scaffold  3.2
• To use clot based biological scaffolds to show that synovial 
derived  MSC rapidly adhered to this structure.  
 Obtaining MSC from the synovium in vivo 3.3
• To show that synovial brushing generated functional colony 
forming unit – fibroblasts (CFU-Fs)  
• To develop a purpose made device to release SY MSC and show 
that the released cell fraction was greater than trapped cells in 
brush bristles, confirmed by CFU-F and DNA analysis.  
• To show that released MSC from synovial tissue following 
expansion demonstrated trilineage differentiation, and 
Immunophenotyping using Flow cytometry. 	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Chapter 2 	  
This work initially used a Papanicolaou smear brush (PAP brush) to assess the 
feasibility of release MSC from the synovium.  Excised synovium was used from 
human knee joints following elective total knee replacement procedures. In addition 
porcine synovium from freshly slaughtered pigs obtained from the local abattoir were 
used. Both sources of synovium were used in initial ex vivo experiments, to assess the 
feasibility of release MSC, and to determine an optimal device design, which allowed 
maximum release and minimal trapping of cells during synovial brushing. To further 
explore MSC release, human in vivo experiments were undertaken initially using the 
PAP brush to evaluate in vivo MSC release, during an elective arthroscopy procedure. 
The final experiments were focused on use of the purpose built MSC releasing device 
(conclusive design) within an in vivo setting; this was undertaken during an elective 
arthroscopy procedure. The numbers of cells released using the purpose built device 
were compared to cells released, during use of the PAP brush in vivo.  	  
4. Materials and Methods 
Please refer to appendix 1 for materials and media used.  
 
 Obtaining MSC from the synovium ex vivo  4.1
4.1.1 Device development  
The design of the purpose made device to release SY MSC, was continuously 
improved, using quantification methods described below.  The approach was focused 
on optimal cell release and minimal cell entrapping.  
4.1.2  Collection of porcine synovium 
Porcine hind legs freshly slaughtered were obtained from the local abattoir and 
transported within 4 hours to the laboratory, where processing took place within 2 
hours. The synovium was dissected out of the knee, with the patella intact for ease of 
use when sectioning. Dissection was undertaken in sterile conditions using laminar 
airflow. The tissue was stored in PBS (Dulbecco's phosphatase buffered saline, 
Gibco®, Invitrogen) until further use (n= 11 porcine legs).  
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4.1.3 Collection of human synovium 
Ethical approval was granted by the National Research Ethics Committee Yorkshire 
and the Humber – South Yorkshire. All patients provided informed consent (refer to 
appendix 2). Patients with a median age of 71.25 years old (50.5-89.5) undergoing 
elective total knee arthroplasty participated in this study (n= 22 donors).  The synovium 
(placed into sterile 0.9% saline) was transported within an hour of extraction to the 
research laboratory for processing in sterile conditions.   
4.1.4 Release of MSC from the human and porcine synovium 
Under laminar flow the synovium was cut into sections approximately 1cm2. Each 
section of human synovium was placed into 10mL of StemMACS MSC expansion 
media. Using forceps to anchor the synovium, 15 vertical strokes of a device were 
applied to release MSC from the synovial lining; this step was repeated for each device 
prototype using a different synovium section, after which CFU-F assays were set up 
(section 4.2). For each assay, 850 µL/well of the expansion media that contained 
released human MSC from each device, was placed into a 6 well plate in triplicates 
and was supplemented with 2 mL of expansion media. Cultures had twice weekly half 
media changes for up to 14 days. Porcine synovium MSC were released into 10mL of 
PBS, and the released cells were analyzed using a DNA quantification method as 
described in section 4.6 and 4.7. 
 Colony forming unit - fibroblast assay (CFU-F) 4.2
CFU-F assays were performed on released MSC from human synovium for 
quantification. Cells were cultured for 14 days at 37 oC, 5% CO2 with twice weekly half 
media changes.  Media was removed after 14 days and the plates were washed twice 
with PBS. The colonies were fixed with 3.7% formaldehyde (3 mL) at room temperature 
(RT) for 15 min. After removing the formaldehyde, 3 mL of 1% methylene blue in 10mM 
borate buffer (pH 8.8) was added for 10 min to stain the colonies. After washing with 
PBS, plates were left overnight to dry before counting the colonies. CFU-F numbers 
from triplicates were averaged, and plotted, comparing device prototypes.  
 Expansion for human SY MSC 4.3
Following CFU-F assay, the remaining cells released from each donor were pooled 
and incubated at 37oC, 5 % CO2 in a 150 cm2 flask in 20mL expansion media. Twice 
weekly half media changes took place until cells reached 90% confluence, at which 
point cells were passaged, until adequate cells for trilineage differentiation were 
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obtained. Passaging of MSC was performed by removing the expansion media and 
washing carefully with PBS to remove any non–adhered cells. After removing the PBS, 
5 mL 0.05% trypsin/EDTA solution was placed into the flask for up to 5 min at 37oC to 
detach the MSC from the plastic. Trypsin containing MSC was supplemented with a 
further 5mL of DMEM (Dulbecco's modified eagle's medium) supplemented with 10% 
FCS (foetal calf serum) and standard antibiotic mixture (100 units/ml penicillin and 100 
µg/ml streptomycin P/S) (refer to Appendix 1). Washing the flask with an equal volume 
of DMEM supplemented with 10% FCS and P/S, was used to collect remaining MSC in 
the flask. MSC were centrifuged for 5 min at 500 x g. The pellet was re-suspended in 1 
mL of DMEM and cells counted (section 4.4). MSC were expanded to passage 3-5, at 
which point they were cryopreserved (section 4.5).  
 Cell counting 4.4
Cells were re-suspended in 1 mL DMEM then a 1:1 dilution with 0.4% trypan blue was 
made and placed onto a haemocytometer. Cells were counted in three different grids, 
and used to calculate the number of cells per ml of cell suspension.  
 
[Mean number of cells X dilution factor] x 10,000 = number of cells/ ml 
 
 Cryopreservation and Recovery of MSC 4.5
Freezing media consisting of FCS and 10% dimethyl sulfoxide (DMSO) was used for 
cryopreservation. Following trypsinisation MSC were pelleted by centrifugation at 500 x 
g for 5 min and re-suspended in 1 mL of the freezing media. Mean number of cells 
within a cryovial was approximately 1.0 x 106. The cells were placed into a “Mr Frosty” 
(Nalegene container) containing isopropanol and placed in -80oC. Recovery of frozen 
cells was done by placing the cryovials into a water bath (37 oC), once thawed cells 
were placed into 10 mL of warm 90 %DMEM + 10% FCS (P/S), centrifuged and 
counted (section 4.4).  
 Cell lysis for DNA extraction  4.6
To obtain DNA for cell quantification, cells released from the relevant synovium were 
centrifuged at 1000 x g for 5 min in 10mL of PBS. The supernatant was discarded and 
cell pellet was re-suspended in 100µL lysis buffer, supplemented with 600µg/mL 
Proteinase K (refer to appendix 1). Cells that were trapped within the bristles of the 
device head were also submerged overnight in a 1000µL lysis buffer.  
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 Phenol-cholorform DNA extraction  4.7
Following cell lysis (section 4.6) 500 µL of cells in lysis buffer was supplemented with 
50 µL (2M) sodium acetate DEPC (diethylpyrocarbonate), 500 µL acid phenol (pH 5), 
and 100 µL red chloroform isoamylalalcohol 24:1. Samples were vortexed and placed 
on ice for 10 minutes, this step was repeated. Samples were centrifuged at 13,000 x g 
for 20 minutes at 40C the top aqueous layer was carefully removed (approximately 450 
µL) to which an equal volume of chilled (-200C) Propan-2-ol was added, and mixed 
thoroughly. All samples were placed in -200C for 2 hours, to allow for DNA to 
precipitate. Samples were centrifuged at 13,000 x g for 30 minutes at 40C, following 
which, the supernatant was discarded and 400 µL of chilled (-200C), pellets were 
washed using 70 % ethanol.  Pellets were allowed to air-dry at RT for up to 60 minutes. 
Once dry 50 µL of DEPC treated water was added to each sample. DNA quantification 
was undertaken using the NANO-drop reader. DNA extracted samples were incubated 
for 30 minutes in 550C water bath and vortexed. Analysis of DNA quantification used 1 
µL per sample, on a NanoDrop® ND-1000 Spectrophotometer and the samples 
analyzed using Thermo Scientific (NanoDrop 1000 3.8.1) software, which gave 
readings in ng/µL. To adjust for difference in volume between those cells released and 
trapped on the brush head” Released cell sample were multiplied by a factor of 5, to 
account for dilution  	  
 MSC trilineage differentiation  4.8
MSC released from human synovium for each device prototypes were culture 
expanded separately for each donor, as described section 4.3. Trilineage differentiation 
into osteogenic, adipogenic and chondrogenic lineages was performed. 	  
4.8.1 Osteogenic differentiation  
Osteogenic differentiation required 3.0 x 104 MSC per well within a six well plate. Basic 
media was prepared (refer to appendix 1) and supplemented with dexamethasone 
(100nM) at the time of media induction and changes. Half media changes took place 
twice a week. Alkaline phosphate (an early osteoblast marker) staining was undertaken 
at 14 days for qualitative analysis. Media was removed, and cells in the wells were 
fixed using fixative (citrate working solution (2 mL citrate concentrate + 98 mL dH20) 
and acetone at 2:3 ratio), for 30 seconds and washed with deionised water. Fast blue 
salt solution (48mL of dh2o + 2mL of 0.25% Naphthol + 1 FAST blue tablet) was added 
to each well and incubated at RT for 30 minutes in the dark. Wells were wash twice 
with dh2o, then 2mL of Mayer’s haematoxylin was added for 10 minutes, and washed 
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with PBS. Wells were visualised using a light microscope and each well was digitized 
using a flatbed scanner. Alizarin Red (evaluates calcium-rich deposits produced by 
osteoblasts) staining was undertaken at 21 days for qualitative analysis. Media was 
removed and cells in the wells were fixed with 2mL ethanol (cooled at -20oC) and 
incubated for 60 minutes. Ethanol was removed and wells were carefully washed three 
times with distilled water. Alizarin red solution (684mg in 50mL of distilled water, pH 
adjusted to 4.1) was placed in each well and incubated for 10 minutes before being 
washed twice with distilled water. Wells were visualised using a light microscope and 
each well was scanned for data storage. " 
The analysis of total calcium production for quantitative analysis of osteogenesis took 
place at 21 days. Media was removed from each well and washed twice with calcium- 
free PBS. To extract deposited calcium, 1 ml of 0.5M hydrochloric acid was added to 
each well and incubated for 5 minutes at room temperature (RT). Using a cell scraper, 
the well content was removed and transferred into a 1.5 ml Eppendorf tube. The 
sample was mixed at 4oC for four hours, using a circular rotating machine. Calcium 
assay was performed using a commercial available kit (refer to appendix 1) using 
calcium standards of 0, 1.5625, 3.125, 6.25, 12.5, 25, 50 and 100 µg/µL. Working dye 
solution was made with reagent 1 and reagent 2 (5:2 ratio) from the sentinel kit, from 
this 196 µL was placed into a 96 well plate, and to this 4 µL of a sample was added. 
This was repeated for all samples and standards, and was incubated for 10 minutes at 
RT in the dark. The samples with the 96 well plate had their optical density read at 
570nm using the GENios microplate reader. Total calcium content was calculated from 
the standard curve generated using calcium standards. Each donor had assays 
undertaken in triplicate; the coefficient of variation between triplicates was 27.74 %, 
thus demonstrating satisfactory assay performance 
 
4.8.2 Adipogenic differentiation 
Adipogenic basic media was prepared (refer to appendix 1) and supplemented with 
hydrocortisone (500 µM) at time of induction and half media changes twice a week. For 
qualitative experiments, 5.0 x 104 MSC were seeded in a 24 well plate to undergo Oil 
Red-O staining. Oil Red-O staining is a method of assessing adipogenesis, at day 21 
from induction. For this, adhered cells were first fixed with 3.7% formaldehyde. Filtered 
0.5% Oil Red was next placed into each well for 10 minutes at RT, following a wash 
with PBS, filtered haematoxylin was added for 45 seconds, and then washed in cold 
tap water. Stained cell lipid vacuoles were visualised using the Olympus CKX41 light 
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microscope. Quantitative experiments were undertaken using 4.0 x 104 MSC seeded in 
triplicate in 48 well plates, on which a Nile red assay at 21 days was performed, using 
Nile red:DAPI ratio to assess lipid content per cell. Nile red dye is almost non-
fluorescent in water and other polar solvents, but undergoes fluorescence 
enhancement and large absorption and emission (blue shift) in non-polar environments 
such as lipids (excitation 535). Using DAPI (4',6-diamidino-2-phenylindole) that binds to 
DNA. Large Nile red:DAPI ratios denote high lipid concentration per cell. Cells were 
fixed in 3.7% formaldehyde after being washed with 500 µL of PBS, baseline readings 
were taken using the Berthold plate reader. After discarding each wells content, 200µL 
of 0.2% Saponin (in PBS) was placed into each well and supplemented with 2µL of 
DAPI and 2µL Nile red stock (working dilution of 1:2000 in PBS), and incubated for 15 
minutes, in the dark. Contents were removed from each well, and washed three times 
with PBS. Finally, 200µl PBS was placed in each well and the plates were covered in 
foil, to incubate. Readings of DAPI and Nile red were taken in the Berthold plate 
reader. The background reading was subtracted from Nile red and DAPI readings from 
the same wells, giving a true reading in each well, Nile red: DAPI ratio were next 
calculated and plotted.   
4.8.3 Chondrogenic differentiation 
Chondrogenic basic media was used (refer to appendix 1) and supplemented with 
transforming growth factor beta 3 (TGFβ3) (2 µg/mL), dexamethasone (100nM), and 
insulin transferrin sodium solution (ITS+) at the time of media induction and changes. 
Half media changes took place three times a week, for 21 days. To maintain gas 
exchange, lids on the Eppendorf used for chondrogenic cultures, were loosened. Cell 
pellets were created using 2.5 x 105 MSC in 1.5 mL microtubes by centrifuging for 5 
min at 2000 x g. For qualitative analysis pellets were frozen in optimal control 
temperature reagent (OCT), sectioned and stained with toluidine blue, which stains 
cartilaginous extracellular matrix purple, and fibrous tissue blue. Glycosaminoglycan 
(GAG) assay was performed for quantitative analysis of produced GAGs. Their 
concentrations were measured against a standard curve, and interpolated to give a 
total GAG/pellet concentration. For GAG measurements, triplicate pellets of each 
donor were digested in 200 µL of papain enzyme digestion solution (100mM Sodium 
buffer, 5mM EDTA, 10mM L-cysteine, 0.125 mg/ML papain) at 65oC overnight, then 
were centrifuged at 15,000 x g for 10 minutes and re-suspended in 100 µL of deionized 
water.  From each sample 50 µL was analyzed for their GAG content using BlyscanTM 
Sulfated Glycosaminoglygan assay kit equipped with GAG standards of 1.0, 2.0, 3.0, 
4.0, 5.0 µg per 100 µL of deionized water. Blyscan dye reagent (1mL) was added to 
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each tube and mixed by repetitive inversion for 30 minutes, at which point sulphated 
GAG-dye complex forms and precipitates out from the soluble unbound dye. The 
sample was next centrifuged at 12,000 x g for 10 minutes, and the supernatant 
removed, after which 500 µL of dissociation reagent was added to the remaining pellet, 
to dissolve the dye, and centrifuged again at 12,000 x g for 10 minutes. From each 
sample 200 µL was transferred into a 96 micro-well plate for analysis using the 
Berthold plate reader, measuring absorbance (656nm).  
 Adhesion and migration of MSC with relevant biological scaffolds 4.9
So far the study has focused on the ability to release MSC from the synovial lining. The 
following methods were next utilized to study how these released MSC were able to 
attach to and migrate through biological scaffolds, aiming to imitate an environment 
similar to one following a microfracture procedure (section 1.7).   	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 Formation of platelet poor plasma (PPP) and platelet rich plasma (PRP) 4.10
scaffold 
Healthy volunteers with no hematological disorders were recruited and informed 
consent was obtained (refer to appendix 2) From each donor, 15 mL of venous blood 
was collected into 3.2% sodium citrate anticoagulation blood collection tube. Samples 
were centrifuged at 250 x g for 10 min. The supernatant was removed and centrifuged 
again at 1500 x g for 10 min (Araki et al, 2012). Following the second centrifugation, 
the supernatant was considered to be platelet poor plasma (PPP). PRP was created by 
centrifuging 4/5th of the collected PPP supernatant at 1500 x g for 10min and mixing 
the platelets formed at the bottom of the tube with a 1/5th of PPP total volume. The 
scaffold was prepared in the lid of an Eppendorf tube, with 200 µL PRP supplemented 
with 4 µL of 5M calcium chloride (CaCL) and 10 µL thrombin (1000U/mL), to allow for 
rapid scaffold formation.  
 Formation of whole blood (WB) scaffold 4.11
Each donor had 5 mL of venous blood collected into a 3.2% sodium citrate 
anticoagulation blood collection tube. The scaffold was prepared in the lid of an 
Eppendorf tube, with 200 µL WB supplemented with 4 µL of 5M CaCL and 10 µL 
thrombin (1000U/mL), to allow for rapid scaffold formation. 
 Formation of Fibrin glue (FG) scaffold  4.12
Fibrin glue scaffolds was prepared in the lid of an Eppendorf tube, with 23.7 µL/ml 
fibrinogen supplemented with expansion media, up to a volume of 200 µL, to which 4 
µL of 5M CaCL and 10 µL thrombin (1000U/mL) was added. The common coagulation 
pathway describes that supplementation of fibrinogen with thrombin and calcium, 
produces a stable fibrin scaffold. 
 Formation of human platelet lysate (hPL) scaffold 4.13
PRP from three healthy individuals was used to prepare hPL. All three PRP samples 
were pooled and were frozen at -80oC for 24 hours and thawed at 4 oC for 24 hours, 
this cycle was repeated once, which allowed the platelets to lyse.  Scaffolds of 200 µL 
hPL supplemented with 4 µL of 5M CaCL and 10 µL thrombin (1000U/mL), were next 
made. 
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 Sectioning and staining of scaffolds 4.14
Scaffolds were placed in optimal cutting temperature solution (OCT) and frozen using 
liquid nitrogen and stored -80 oC until use for cells counting. Using a Cryostat, 10µm 
sections were made and placed onto glass slides and H&E staining was performed so 
that cell nuclei could be visualised and counted using Image-J 1.48V software. 
 Imaging and MSC cell quantification in scaffolds 4.15
Images were taken across the extent of the scaffold, to assess for its size, and shape 
at x4 and x10 magnification. The number of cells/mm2 was calculated using Image-J 
1.48V software. H&E stained cells were counted within scaffolds and on the edge of 
the scaffolds and compared for each scaffold type (number of cells/mm2 was plotted 
against scaffold type).	  
 Adhesion of MSC to relevant biological scaffolds 4.16
Following preparation of the three biological scaffolds, PRP (n=3 donors), WB (n = 3 
donors) and FG (n = 1) (section 4.10, 4.11 and 4.12), 1mL of expansion media 
containing 10,000 MSC (culture expanded SY MSC from donor 4, see table 2) was 
placed into an Eppendorf tube, with the scaffolds formed in the Eppendorf lid. After 
closing the lid, the Eppendorf tube was inverted to allow cells to adhere to each 
scaffold type  (see Figure 10). Non-adherent cells in the supernatant where removed 
and placed in culture to attach to tissue culture plastic overnight. Thereafter, cells were 
fixed in 3.7% formaldehyde (1 mL) at room temperature (RT) for 15 min. After 
removing the formaldehyde, 1 mL of 1% methylene blue in borate buffer pH 8.8 was 
added for 10 min to stain the cells allowing for it to be visualised and counted using 
Image-J 1.48V software, this was repeated in triplicates at each time point for each 
scaffold type. The percentage of adhered MSC was calculated, using the following 
formula: 
 
% Adhered cells = (initial MSC seeded for adherence – non-adhered MSC)x 100 
 
MSC were counted for each biological scaffold, and subtracted from initial MSC 
number. The percentage of adherence was then plotted as a percentage to determine 
if adhesion was affected by MSC donor variation, the above assay was repeated using 
three MSC donors, with one FG scaffold type.  
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Figure 10. Adhesion assay: Eppendorf set up with MSC suspended in expansion 
media, inverted for a set period of time, and non-adhered cells placed in culture to 
attach to tissue culture plastic overnight, fixed in 3.7% formaldehyde, stained with 1% 
methylene blue and quantified using Image-J 1.48V software.  
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 Migration of MSC towards relevant biological scaffolds 4.17
Migration abilities towards biological scaffolds such as PRP and hPL were investigated. 
Preparation of PRP (section 4.10), hPL (section 4.13) in liquid form (without 
supplementation of CaCl and thrombin), as well as negative control (DMEM + 0.5% 
foetal calf serum FCS) and positive control (DMEM + 10% FCS) media were used. 
Each chemokine, as well as the positive and negative controls (750 µL) were placed 
into a separate well of 24 trans-well plates. The transwell insert with 8 µm pores 
containing 105 MSC/insert, in serum starved media (DMEM + 0.5% FCS), from a single 
donor (p4) was inserted into each well. Migration was allowed to take place over 4 and 
24 hours. This was repeated in duplicates with different MSC and PRP donors, to take 
in account of donor variations (see Figure 11). Following migration period the 
membrane of the trans-well, was fixed in 3.7% formaldehyde, stained in hematoxylin 
and eosin (H&E) solution, and quantified using Image-J 1.48V software. 
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Figure 11:	   Modeling MSC migration toward biological scaffold.	   Trans-well 
migration assay within a well of 24 well plate and trans-well inserts.  Wells were 
seeded with 105 MSC/insert allowing for MSC in serum-starved media to migrate 
toward liquid constituents of differing biological scaffolds (PRP or hPL or positive 
control or negative control). Following migration period of either 4 and 24 hours, the 
membrane of the trans-well, was fixed in 3.7% formaldehyde, stained in H&E solution 
and quantified using Image-J 1.48V software 
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 Migration of MSC through relevant 3D biological scaffolds  4.18
The focus of this part of the study was to determine if released MSC could migrate into 
and through biological scaffolds. To allow cells to migrate from below the scaffold, 
sterile molds were created, using 1 mL cylinders (cut from a Pasteur pipette) placed on 
a paraffin wax wrap. Platelet poor plasma (PPP) and PRP scaffolds to the volume of 
200 µL were formed inside these molds (refer to 4.10), and placed on top of a 
previously prepared mono-layer of MSC (105 per well), in a six well plate containing 
expansion media (prepared 24 hours prior to scaffold placement, to allow for adhesion 
of MSC to the plastic). Twice weekly media changes took place for all formations for a 
total of 10 days at which point scaffolds were fixed (Mendelson et al, 2011). Scaffolds 
were fixed in 3 mL of 3.7% formaldehyde, sectioned and stained in H&E. Cell nuclei 
could be visualised and counted using Image-J 1.48V software; this was performed in 
triplicate (see Figure 12).  
 
To allow cells to migrate from above the scaffold cells were seeded using the following 
method. Agarose gel wells were made, using 3 mL of 4% agarose in a 6 well plate. 
Once the gel set, 8 mm diameter wells were created using a borer; PRP and PPP 
scaffolds of 200 µL were formed within this 4% agrose well and MSC were seeded at a 
density of 105 MSC/well in expansion media (Mendelson et al, 2011) (see Figure 13). 
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Figure 12: Migration through biological scaffolds (from below). (A) PRP and PPP 
formed using a plastic molds. (B) PPP and PRP scaffolds placed on top of a monolayer 
of 105 MSC/well in expansion media. Following 10 days of migration, scaffolds were 
fixed in 3.7% formaldehyde, sectioned and stained in H&E solution. Number of cells 
was quantified using Image-J 1.48V software. 
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Figure 13: Migration through biological scaffolds (from above). PPP and PRP 
scaffolds within constructed agarose cast constructed. MSC (105) seeded from above 
in expansion media. Following 10 days of migration, scaffolds were removed from the 
cast, fixed in 3.7% formaldehyde, sectioned and stained in H&E solution (Number of 
cells was quantified using Image-J 1.48V software. 
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 Investigation of cell type, migrating through relevant 3D biological 4.19
scaffolds 
To investigate the type of cells migrating through a 3D biological scaffold, the following 
experiment was undertaken.  MSC (105 MSC/well) were seeded in a 6 wells plate, to 
migrate through a PRP (n = 2 donors) and an hPL (n=1) scaffold for a time period of 2, 
5 and 10 days. As a control, the PRP scaffolds were placed in wells containing no 
MSC. MSC from culture-expanded TKR synovium were used as the migrating cells. At 
2, 5 days and 10 days scaffolds were taken out of the wells, fixed in 3 mL of 3.7% 
formaldehyde, sectioned and stained in H&E staining performed, so that cell nuclei 
could be visualised and counted using Image-J 1.48V software, this was repeated in 
triplicate at each time point (see Figure 14). 
 Dual-staining of SY MSC and leucocytes with surface marker specific 4.20
primary antibodies 
Using PRP, from one healthy individual, a 3D biological scaffold was created, and 
culture expanded SY MSC from one donor, were embedded into each scaffold. The 
scaffolds were fixed with 3.7% formaldehyde, placed in OCT and frozen using liquid 
nitrogen, until sectioning (section 4.14). Sectioned PRP scaffolds were stained with 
CD73 (for MSC) and CD45 (for leukocytes) primary antibodies using the EnVisionTM 
G|2 Doublestain system, (see appendix 1 for full protocol). This specific dual staining 
experiment has not been undertaken previously. However, previous studies using 
primary antibodies staining method (Letouzey et al, 2015), were used as a guide, 
coupled with the instruction from the staining kit (refer to appendix 1). Stained cells 
were visualised using the Olympus CKX41 light microscope. 
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Figure 14: Investigation of type of cells migrating. Migration of MSC through a hPL 
and PRP scaffold. Wells were seeded with either 105 MSC/well or not seeded, as a 
control.  Following 2, 5 and 10 days of migration period, scaffolds were removed from 
wells, fixed in 3.7% formaldehyde, sectioned and stained in H&E solution. Cell 
numbers was measured using Image-J 1.48V software.  
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 MSC migration through 3D biological scaffolds, using dual-staining of MSC 4.21
(CD73) and leucocytes (CD45) with surface marker specific primary 
antibodies 
Biological scaffolds (PRP and PPP), were set up as described in section 4.10. 
Scaffolds were placed on a monolayer of MSC, as described in section 4.18, allowing 
for migration to occur. In addition, a PRP scaffold was placed in a well with no 
monolayer of MSC, as a negative control. After 10 days, all scaffolds were dual stained 
as described in section 4.20.   	  
In vivo experiments were undertaken using two devices, during elective knee 
arthroscopies in different donors for each device (refer to table 2 and 3). The first set of 
in vivo experiments was undertaken using the Papanicolaou smear brush (PAP brush), 
to assess in vivo release of MSC from the synovium. The second set of in vivo 
experiments was undertaken using the purpose built MSC releasing device (refer to 
appendix 1 for images of both devices). Both experiments involved these devices being 
used in human knee joints  
 Collection of MSC from human synovium during arthroscopy using the 4.22
PAP brush in vivo 
Ethical approval was granted by the National Research Ethics Service Committee 
Yorkshire and the Humber – South Yorkshire. All patients provided informed consent 
(refer to appendix 2). Patients with a median age of 29.5 years old (18.1-52.0) 
undergoing elective knee diagnostic/therapeutic arthroscopies participated in this study 
(n=9).  Three samples were collected from each donor, these consisted of 1) synovial 
fluid (SF), which in some cases was supplemented with saline, to aid in extraction. 2) 
Irrigation fluid, which was collected following the planned procedure (i.e. debridement) 
and 3) post brushing of the synovium with the device. SF was collected in a sterile 
container, with a mean volume of 37mL (5-50mL), the irrigation sample was collected, 
mean volume 39mL (25-50mL), and finally following brushing of the synovium (to 
release of MSC), the post brushing sample was collected, mean volume 53mL (50-
70mL), all samples were transported within an hour of extraction to the research 
laboratory for processing in sterile conditions.  Samples were centrifuged at 500xg for 5 
minutes and re-suspended in 10mL of expansion media. Each sample, had 2 mL of cell 
suspension placed in a 10cm petri dish, which was supplemented with 8 ml of 
expansion media (1/5 dilution factor). This was done in duplicate, for each sample. 
CFU-F assay was used to quantify released numbers of MSC (section 4.2). The 
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remaining suspensions were pooled for each sample, and culture expanded as per 
standard protocol (section 4.3). Expansion of cells took place with twice weekly half 
media changes, until samples reached 90% cell confluence, at which point cells were 
passaged, as described in section 4.4, to a minimum of 1.0 x 106 per sample, and were 
the cryopreserved for later use (section 4.5).  
 MSC trilineage differentiation of in vivo released synovial MSC 4.23
Osteogenic differentiation was conducted using standard method as described above 
(section 4.81). Adipogenic differentiation was conducted using standard method as 
describe above (section 4.82). Chondrogenic differentiation was conducted using 
standard method described above (section 4.83). However, for MSC released using  in 
vivo PAP brush commercially supplied Chondrogenic media StemMACS ChondroDiff 
Media (Miltenyl Biotec, MACS®) was used.  
 
 Surface phenotype of cultured SF MSC and SY MSC by flow cytometry 4.24
Flow cytometry phenotyping of SF MSC (SF) and SY MSC (post-brushed) was 
performed using a LSRII four laser flow cytometer (BD Biosciences, Oxford, UK) with 
appropriate isotype controls. Synovial fluid MSC passage 5 and SY MSC passage 7 
(n=1 donor) were trypinised and re-suspended at 1x106 cells/ml. To block non-specific 
antibody binding, cells (1x106) were incubated for 15 minutes with blocking buffer (10% 
mouse serum, 1% Human IgG in FACS buffer) supplemented with  (FACS buffer PBS 
+ 0.1%BSA) at RT. The following commercially available antibodies were used at 
manufactures recommended dilutions: anti-CD34- allophycocyanin-cyanine (APC), 
anti-CD19- phycoerythrin (PE), anti-CD45- phycoerythrin-cyanine (PE-Cy7), anti-
CD14- fluorescein isothiocyanate (FITC), anti-CD73- phycoerythrin (PE), anti-CD90- 
phycoerythrin-cyanine (PECy7), anti-CD105- phycoerythrin (all from BD Biosciences). 
Cells were stained with 4′,6- diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) as a cell 
viability marker and in order to gate out dead cells. At least 10,000 live cell events were 
collected for each antibody combination (Baboolal et al, 2014).  
 Obtaining MSC from the SF and SY using the purpose made device to 4.25
release SY MSC, in vivo 
The following experiments were aimed to demonstrate in vivo release of MSC from 
human synovium using a purpose built synovial device. Ethical approval was granted 
by the National Research Ethics Service Committee Yorkshire and the Humber – West 
Yorkshire. All patients provided informed consent (refer to appendix 2). Patients with a 
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median age of 33.7 years old (22.0-53.7) undergoing elective knee 
diagnostic/therapeutic arthroscopy participated in this study (n=10).  The SF was 
collected through the arthroscopy ports. In some cases SF was not easily expelled 
through the ports, in such cases a standard volume (20ml) of sterile 0.9% saline was 
introduced via the ports site, and the SF/saline mix was collected. During the patient’s 
planned arthroscopy procedure, a sample of initial irrigated knee content was collected, 
which contained the SF MSC. After completing the planned procedure (for example 
microfracture) the surgeon would irrigate the joint, with saline, to wash away any debris 
created, following which, a sample would be collected. The surgeon then introduced 
the synovial device brush into the knee via the port site and brushing of the synovium 
took place, allowing for the release of the SY MSC. The knee was irrigated and a post-
brushed sample was collected via the arthroscopic ports, this sample would contain SY 
MSC. The three samples were transported within an hour of extraction to the research 
laboratory for processing in sterile conditions.   
 Sample processing of SF and SY MSC from in vivo device brushing 4.26
All three samples: SF, irrigation and post-brush samples were centrifuged at 500 x g. 
Pellets were re-suspended in 1mL of DMEM media and cell number counted (section 
4.4). All three samples were re-suspended in 9mL of StemMACS MSC expansion 
media (Miltenyi Biotec, UK). Each sample, had 2 mL of cell suspension placed in a 
10cm petri dish, which was supplemented with 8 ml of expansion media (1/5 dilution 
factor). This was done in duplicate for each sample. CFU-F assay was used to quantify 
released numbers of MSC (section 4.2). The remaining suspension of cells in SF, 
irrigation and post-brushed were culture expanded until a minimum of 1x106 cells were 
attained, and then cryopreserved (section 4.5), for future use in differentiation assay.  
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5. Results 	  
 Obtaining MSC from the synovium ex vivo 5.1
The knee has an endogenous supply of MSC in the form of SF MSC. SF MSC, 
phenotypically are similar to BM MSC (Jones et al, 2008; Sekiya et al, 2012), and 
demonstrate better, more consistent chondrogenic capabilities. A further advantage of 
SF MSC is the greater number of cells present in arthritic knees, compared to non-
arthritic knees (Jones et al, 2008). However, in a knee arthroscopy procedure SF MSC 
will be lost during irrigation. To replace these cells, another source of endogenous 
autologous MSC can be used, such as SY MSC (De Bari et al, 2001). Comparable to 
SF MSC, SY MSC demonstrate chondrogenic abilities, and express better 
chondrogenic potentials than BM MSC and IFP MSC (Sakaguchi et al, 2005; Fan et al, 
2009). Previous studies undertaken in Leeds MSC group laboratory, showed effective 
ex vivo release of MSC from the synovial surface using a PAP brush.  The focus of this 
study was to optimize the release and minimize the entrapment of cells within the 
bristles of a device, as well as design a new purpose built device to release SY MSC 
from the synovial surface. This purpose built device was designed for use in man, and 
its main function was aimed at the augmentation of the total number of endogenous 
MSC within the knee following an arthroscopy procedure.  
 
Using the PAP brush as a control, a purpose made device to release SY MSC, was 
developed, using both porcine and human synovium as a source for SY MSC. Porcine 
synovium provides a consistent aged synovium, and was the synovium of choice for 
DNA analysis to minimize variability. Porcine synovium was used for quantification of 
cells; released and trapped within the device bristles. Human synovium was used to 
undertake CFU-Fs assays for quantification of released MSC. Due to the variation in 
section size of human synovium samples collected, not all devices could be used to 
brush the synovium during consecutive sample, please refer to table below (see Table 
2).  	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Table 2: An overview of human synovial donors, used for the development of the 
purpose made device to release SY MSC. Highlighted rows (n=6 donors), are SY MSC 
donors used in trilineage differentiation experiments. (OA =osteoarthritis, TKR = total 
knee replacement). 
 	  	  	  	  	  	  	  	  
Donor Age Gender Disease 
Type 
Surgery 
 
Device Concept Type Used 
PAP C1 C2 C3 C4 C6 C7 C8 
1 73.7 F OA TKR ✔  ✔  ✔ ✔ ✔  
2 71.4 F OA TKR ✔  ✔  ✔ ✔ ✔  
3 82.7 F OA TKR ✔  ✔  ✔ ✔ ✔  
4 50.5 F OA TKR   ✔  ✔ ✔ ✔  
5 70.8 M OA TKR   ✔      
6 67.6 F OA TKR ✔  ✔  ✔    
7 72.8 M OA TKR ✔ ✔ ✔ ✔ ✔    
8 86.8 F OA TKR ✔ ✔ ✔ ✔ ✔    
9 58.1 F OA TKR ✔ ✔ ✔      
10 66.5 M OA TKR ✔ ✔       
11 79.2 M OA TKR ✔     ✔ ✔  
12 77.9 M OA TKR ✔       ✔ 
13 62.4 F OA TKR ✔       ✔ 
14 64.2 F OA TKR ✔      ✔ ✔ 
15 57.6 F OA TKR ✔      ✔ ✔ 
16 85.3 F OA TKR  ✔ ✔ ✔ ✔    
17 79.1 M OA TKR  ✔ ✔ ✔ ✔    
18 64.2 F OA TKR  ✔ ✔ ✔ ✔    
19 89.5 F OA TKR  ✔ ✔ ✔ ✔    
20 64.8 M OA TKR  ✔ ✔ ✔ ✔    
21 89.1 F OA TKR ✔      ✔ ✔ 
22 71.1 F OA TKR ✔      ✔ ✔ 
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 Quantification released and trapped cells within the device bristle, using 5.2
cells from porcine synovium 
Freshly slaughtered porcine hind legs were obtained from the local abattoir. Under 
sterile conditions the synovium was dissected out of the knee with the patella intact for 
ease of use when sectioning. The number of cells that were released from the 
synovium and those trapped within the bristles of three prototypes (PAP, C2 and C4) 
(see Figure 15) were quantified by proportionally measuring the cellular content which 
is either released or trapped, in terms of DNA content. This gave an indication of cell 
numbers. The DNA was purified using phenol:chloroform extraction method, and was 
quantified using the NANO-Drop method described in sections 4.6 and 4.7), (n=11 
donors).  
 
Initially it was determined to what degree the prototype synovial brushing devices 
released or trapped synovial cells. Two devices used (PAP and C4) showed no 
statistical significance between DNA content of released cells from the synovium, and 
those trapped within the bristles of the device.  However, device C2 showed statistical 
significance, where more cells were trapped within the bristles compared to release by 
this device (* = p < 0.02, paired t-test) (see Figure 16). 
 
 
 
 
 
 
 
 
 
 
 
 -­‐54-­‐	  
 
 
 
 
 
 
 	   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: SY MSC releasing device prototypes. Variations of prototype brush ends.  
Prototypes C1-C4 are designs, used in initial SY MSC releasing experiments (phase 
1). C6-C7 subsequent phase prototypes designed from initial experiment outcomes 
(phase 2). C8 is the final design used in in vivo experiments (final phase). PAP device 
used in all ex vivo and in vivo work.  
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 Quantification of released MSC from human synovium using CFU-F assays 5.3
To determine the number of viable MSC released from excised human synovium, 
colony forming unit-fibroblast (CFU-F) assays, were used as a method of 
quantification. CFU-F assays were performed with each device by brushing the surface 
of the synovium section of each donor. MSC released from the synovium, formed 
colonies and were fixed and stained at 14 days, these were then counted (see Figure 
17). Results revealed no statistical significant difference between the device prototypes 
used. This data (section 5.2 and 5.3) was used to further develop the prototype design. 
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Figure 16: Release of cells from porcine synovium, phase 1. DNA content of cells 
(ng/µL) released from 1 cm2 sections excised porcine synovium ex vivo experiment, 
and those trapped within the bristles of the device, using PAP and two brushing 
prototypes (C2 and C4). (n=11 donors). C2 (*=p<0.02, paired t-test). 
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Figure 17: Release of MSC from human synovium, phase 1. CFU-F/well (6 well 
plate) data from excised 1 cm2 sections human synovium ex vivo experiment indicating 
released MSC using PAP and the different prototypes (C1, C2, C3, and C4). Data 
represented by median value per device, with upper and lower quartiles and minimum 
and maximum values.	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 Quantification of cells released using modified device prototypes (phase 2) 5.4
Phase 2 of ex vivo experiments using DNA analysis on excised porcine synovium. 
Each synovium was sectioned into multiple 1 cm2 sections, and brushed with phase 2 
modified devices termed C6 and C7 (see Figure 15). Device C6 was developed using a 
combination design of two previous prototypes C2 and C4 and there respective results 
(see Figure 15 and 17). Device C7 was a new design that coupled the bristles design 
feature of both C2 and C4, in a diamond orientation. Results demonstrated no 
statistical significant differences between the two types of devices. (see Figure 18). 
Excised human synovium obtained from patients undergoing elective total knee 
replacement (table 2) was used. Each human synovium section was brushed with 
either C6 or C7 on a donor-matched 1cm2 section of synovium (see Figure 19).  
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Figure 18: Release of cells from porcine synovium, phase 2. DNA content (ng/µL) 
of cells from excised 1 cm2 porcine synovium ex vivo experiment, that were released, 
and trapped within device bristles C6 and 7 (n=11 donors). 	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Figure 19: Release of MSC from human synovium, phase 2. Quantification of 
released MSC from excised human synovium, using CFU-F assays. CFU-F/well (6 well 
plate), data showing released MSC using the device prototypes C6 (n=5 donors) and 
C7 (n=9 donors). Data represented by median value per device, with upper and lower 
quartiles and minimum and maximum values.  
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Results from both human and porcine synovium in phase 2 of device design, 
demonstrated no statistical significant difference between the two types of devices. 
This data was used to further develop the prototype bristle design, in the final phase of 
the study.  
 Quantification of cells released using modified device prototypes (final 5.5
phase) 
Using the data from phase 2 of device concept design, a final device design C8, was 
developed, and compared to the PAP brush as a control. C8 (see Figure 15) was 
design based on the diamond shaped configuration as C7, allowing for cell release to 
occur when multiple brushing directions are used, rather the only a front to back 
motion, thus allowing a greater cell release. In addition, spacing between bristles were 
increased, as data from phase 2, demonstrated that similar numbers of cells were 
being released as well as trapped. So it was proposed that larger gaps between 
bristles would reduce cells being entrapped (see Figure 20).  
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Figure 20: Release of MSC and cells from human synovium, final phase (A) 
Quantification of released MSC using CFU-F assays. CFU-F/well (6 well plate), data 
showing released MSC using the device prototypes C8 (n=6 donors) and PAP (n=6 
donors). Data represented by median value per device, with upper and lower quartiles 
and minimum and maximum values. (B) DNA content (ng/µL) of cells that were 
released from excised human synovium, and trapped within device bristles (n=5 
donors).  
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The above results demonstrated no statistical significance when comparing MSC and 
cells release from human synovium, during brushing with device C8 and the PAP 
brush. Although improvements have been made in the device cell releasing capabilities 
when compared to trapping, there seems to be no significant advantage for the use of 
C8 prototype over PAP brush within an ex vivo setting. However, it is sensible to 
acknowledge that this device demonstrates an effective cell release, which might be 
further enhanced when it is developed into a purpose build device tailored to 
arthroscopy. Dr. Baboolal made all design specifications for each concept with the aid 
of the above results that were obtained by my work. The final purpose built device was 
designed with feedback in consultation with Mr Wall and Mr Calder our orthopaedic 
surgeons.  
 Trilineage differentiation of cultures expanded, SY MSC released from 5.6
human synovium ex vivo 
Cells released from each human synovium were pooled separately for each donor and 
culture expanded. Following expansion these pooled cells were used to demonstrate 
trilineage differentiation into osteogenic, adipogenic and chondrogenic lineages, 
performed on passage 3-5 cells. Osteogenesis was evaluated both qualitatively and 
quantitatively for the SY MSC in triplicate. Alkaline phosphatase staining at day 14 and 
alizarin red at day 21 were performed. Total amount of calcium produced was used to 
quantify osteogenesis at day 21 (section 4.8.1)(see Figure 21).  
All three donors demonstrated ALP at 14 days. At 21 days calcium deposits were also 
identified in all three donors by Alizarin Red staining. Total calcium production over 21 
days was quantified colorimetrically using a standard calcium assay kit, and showed 
calcium production values consistent with SY MSC (Jones et al, 2010).  
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Figure 21: Osteogenesis of ex vivo released SY MSC (A) Examples images of 
alkaline phosphatase and alizarin red staining (n=3 donors). (B) Total calcium/well 
(µg/mL) production (n=6 donors). Each bar represents readings calculated from 
triplicates per donor as mean and standard deviation. These findings demonstrate 
acceptable osteogenic capabilities. 
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Adipogenesis was evaluated both qualitatively and quantitatively, for the released 
passage 3-5 cell cultures in triplicate. At day 21, oil red-O staining was performed to 
visualise lipid-containing vesicles produced by the MSC. Nile red-DAPI ratio was used 
to quantify adipogenesis, where large Nile red:DAPI ratios denote high lipid 
concentration per cell (see Figure 22).  
 
Lipid filled vesicles were observed using oil-red-O staining, and ratios of Nile red 
against DAPI, displayed good yields of adipogenesis (Aldridge et al, 2013), thus 
adipogenic potential was demonstrated in all three donors.  
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Figure 22: Adipogenesis of ex vivo released SY MSC (A) Oil-red-O staining at x20 
magnification for all three donors shows lipid filled vesicles. (B) Quantification of 
adipogenesis assays, using Nile:DAPI ratio, mean value of triplicates, including SD 
(n=3 donors). These findings demonstrate acceptable adipogenic capabilities.	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Chondrogenesis was evaluated both qualitatively and quantitatively. Pellets were 
cultured for 21 days from passage 3-5 cultures of five donors in triplicates. For 
qualitative analysis chondrogenic pellets were sectioned and stained with toluidine 
blue. This stain highlights cartilaginous extracellular matrix purple, and fibrous tissue 
blue. To quantify chondrogenesis, the remaining pellets were digested in papain. 
Sulfated-GAG (s-GAG) precipitate was quantified using the Blyscan™ s-GAG assay 
(see Figure 23).  
 
Chondrogenic potential was demonstrated using GAG quantitative measurements. 
Donor-to-donor variation was observed within the chondrogenic assay; however, 
overall results demonstrate chondrogenesis consistent with SY MSC (Jones et al, 
2010). In summary, overall results for trilineage differentiation of ex vivo culture 
expanded MSC released from human synovium, do indeed show their trilineage 
differentiation capabilities.  
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Figure 23: Chondrogenesis of ex vivo released SY MSC.	   (A) Chondrogenic pellets 
stained with toluidine blue showed GAG stained in purple, and fibrous tissue stained 
blue for three donors.  (B) Total GAG content (µg/pellet) for each sample following 
papain digestion, mean value of triplicates, including SD (n=5 donors). These findings 
demonstrate acceptable chondrogenic capabilities.  
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 Adhesion and migration of MSC within relevant biological scaffolds 5.7
The study so far has demonstrated the ability to release MSC from the synovium 
during an ex vivo experiment. These MSC proliferated ex vivo and had trilineage 
differentiation potential. Previous research has identified these cells as a source of 
highly chondrogenic MSC (Sakaguchi et al, 2005). Current models for using these 
types of cells require a two stage surgical procedure, and cell culture expansion. So far 
this study has shown that these cells can be accessed with a single surgical process, 
and thus become an attractive option in the repair of articular cartilage injuries.  
 
The focus of this section of the thesis was to evaluate the interaction of SY MSC when 
they are allowed to attach and migrate through biological scaffolds. Biological scaffolds 
such as whole blood scaffold (WB) is created by the orthopaedic surgeon during an 
arthroscopy procedure (known clinically as a microfracture) (section 1.6), it allows for 
repair of isolated articular injuries; Fibrin glue (FG), is an effective scaffolds for focused 
MSC delivery within articular cartilage defects (Kim et al, 2015). Platelet rich plasma 
(PRP), known for their delivery of growth factors (GF), that aid in tissue repair (Van 
Pham et al, 2013; Ornetti et al, 2016) and Human platelet lysates (hPL), a more 
immediate source of GF that is released  due to lysis of platelets. This can be a quicker 
source of GF compared to PRP which releases its GF content in a slower manner 
(Jonsdottir-Buch et al, 2013; Radtke et al, 2014; Sellberg et al, 2016).  
 Adhesion of MSC to relevant biological scaffolds 5.8
To quantify MSC adhesion onto biological scaffolds, culture expanded SY MSC from 
donor 4 (table 2) were used. Following the method describes in section 4.16, non-
adhered cells were stained with methylene blue, after being plated overnight to allow 
for plastic adherence. Cells were counted using Image-J 1.48V software. The 
percentage of adhered MSC was plotted using the calculation described in methods 
(section 4.16) (see Figure 24).  
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Figure 24:  Adhesion of MSC to biological scaffolds. (A) After adhesion to a 
biological scaffold, non-adhered MSC from 1 donor were plated overnight, then 
subsequently fixed and stained with methylene blue. Images taken at x10 
magnification. (B) The percentage of adhered MSC to all three biological scaffolds was 
plotted against 5, 30 and 60 minutes. These findings show a rapid adhesion of the 
MSC to all biological scaffolds.   
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It was demonstrated that 25-35% of MSC adhered within 5 minutes, 65-75% of 
adherence took place within 30 minutes, and >80% adhered after 60 minutes, with no 
variation between PRP (n=3 blood donors), WB (n=3 blood donors) and FG scaffold. 
 
To account for potential variation in SY MSC between different donors in their adhesion 
abilities to a biological scaffold, this experiment was repeated with use of a FG 
scaffolds (section 4.12), and three different culture expanded MSC donors (donor 5, 6 
and 7, see table 2). Following the method describes in section 4.16, the percentage of 
adhered MSC was plotted against 5, 30 and 60 minutes (see Figure 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 -­‐72-­‐	  
 
 
 
 
 
 
Figure 25:  Adhesion of MSC to FG scaffold (A) Non-adhered MSC were plated 
overnight, then subsequently fixed and stained with methylene blue (representative 
donor). Images taken at x10 magnification.  (B) The percentage of adhered MSC to FG 
scaffold was plotted against 5, 30 and 60 minutes. These findings show a rapid 
adhesion of the MSC to FG scaffolds.   
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It was demonstrated that 30-40% of MSC adhered within 5 minutes, 75-90% of 
adherence took place within 30 minutes, and no marked change of adherence levels 
up to 60 minutes (75-90%), this trend was similar for donor 5, donor 6 and donor 7 SY 
MSC adherence to FG scaffold. These rapid kinetic interactions are compatible with an 
almost immediate potential for MSC interactions in vivo following MSC release.  
 
Results demonstrate that SY MSC adhesion to biological scaffolds is rapid, with more 
than 65% occurring within 30minutes. In addition, it was shown that no significant SY 
MSC donor variation occurred on adhesion times, when three different donor SY MSC 
where allowed to adhere to a FG scaffold.   
 Migration of MSC towards relevant biological scaffolds 5.9
The focus of this study now will be to investigate migration of SY MSC toward 
biological scaffolds, in the form of PRP and human platelet lysates (hPL). As stated in 
the introduction (section 1.13), PRP is currently used as a therapeutic treatment within 
an arthritic joint, due to its release of growth factors (GF), which aid in regenerative 
articular repair (Mollon et al, 2013). Within a clinical setting, PRP can easily be made 
using the patient own blood. To quantify migration of SY MSC towards biological 
scaffolds with high GF content, PRP and hPL were used. FG was not used for 
migration studies, as one of the aims of this study was to use the patients’ own supply 
of biological scaffold, thus making this procedure cost effective in the clinical setting. In 
addition, WB was not selected for migration studies due to previous studies 
demonstrating an increase level of GF in PRP compared to WB (Lee et al, 2013).	  As 
hPL is known to have a more immediate supply of GF (Jonsdottir-Buch et al, 2013; 
Radtke et al, 2014; Sellberg et al, 2016), it was an ideal scaffold to be used to compare 
migration with PRP.  Using a transwell plate, cultured SY MSC from donor 8 (n=1 
donor, see table 2) were allowed to migrate through 8 µm pores towards liquid form of 
either 10% PRP, 10% hPL scaffold (pooled from 3 donors) or a positive control (10% 
FCS + DMEM) or negative control (0.5 % FCS + DMEM) media, (see Figure 26). 
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Figure 26: Migration of cultured SY MSC towards PRP and hPL. Migration of 
cultured SY MSC (from donor 8, table 3) with 10% pooled hPL compared to 10% PRP 
(three hematological healthy donors), and positive (10% FCS) and negative (0.5% 
FCS) controls, at both 4 and 24 hours. Data represented by mean value of triplicate 
wells of migrated cells. These findings demonstrate favorable migration towards PRP 
and hPL at 24 hours. 	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The results demonstrate SY MSC migration towards both PRP and hPL that occurs 
better at 24 hours compared to 4 hours. In addition, both PRP and hPL demonstrated 
better migration of SY MSC compared to negative control. This study will now 
investigate migration of SY MSC through 3D biological scaffolds. 
 Migration of MSC through relevant 3D biological scaffolds 5.10
Next the migration of SY MSC through 3D biological scaffolds was investigated utilizing 
PRP and PPP. As described earlier, PRP has a supply of GF, and it is expected that 
the lack of platelets within PPP, potentially showed less MSC migration compared to 
PRP, due to the lack of GF in PPP. Migration was allowed to take place over a ten 
days period, following which the scaffolds were sectioned and stained with H&E, 
allowing for migrated cells to be counted (section 4.18), (see Figure 27). 
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Figure 27: Migration of cultured SY MSC through relevant biological scaffolds 
(3D model). (A) Image of putatively migrated SY MSC through PRP and PPP scaffolds 
following 10 days assay (x10 magnification). Green circles highlight some putatively 
migrated cells. (B) This demonstrated higher numbers of cells in PRP scaffolds 
compared to PPP scaffolds (*=p<0.02, Wilcoxon test). Data represented by median 
value of triplicate sections, with upper and lower quartiles and minimum and maximum 
values (n=7 blood donors).  
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These results demonstrated a statistical increase in cells present in PRP biological 
scaffolds compared to PPP biological scaffold, at 10 days of migration. However, it was 
observed that some cells were present in PPP biological scaffolds. As there is some 
platelets remaining in PPP following processing, these platelets could potentially be 
contributing to some GF release, thus could be a cause for a small number of cells to 
migrate through a PPP biological scaffold. Furthermore, it would be important to 
consider that cells that are being counted may not be MSC. Instead these cells could 
be constituents of PRP, for example leukocytes which remained in PRP following its 
preparation (Amable et al, 2013; Lee et al, 2013). To test this, SY MSC in scaffolds 
were investigated further.  
 Investigation of cell type, migrating through relevant biological scaffolds 5.11
(3D model) 
As stated above, higher levels of cell counts in a PRP scaffold compared to a PPP 
scaffold were evident. To verify these cells were MSC, a migration assay was 
performed, to compare PRP scaffolds seeded with MSC and PRP scaffolds not seeded 
with MSC. As a control, hPL was used due to its high GF content, but lack of 
leukocytes. Migration took place over a ten-day period. Two hematological healthy 
PRP donors were used and each donor had one PRP scaffold seeded with cultured SY 
MSC, and another PRP scaffold not seeded with MSC. After the migration period, 
scaffolds were sectioned and stained with H&E, and cells visualised and counted. 
(section 4.19), (see Figure 28).  
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Figure 28: Cells counted within relevant 3D biological scaffolds. (A) PRP donor 1 
and 2, seeded with SY MSC, demonstrate a gradual decline in cell numbers over a 10 
days period. No cells are counted in hPL until day 7. (B) PRP donor 1, not seeded with 
SY MSC, demonstrates a gradual decline in cell numbers over a 10 days period; 
however, PRP donor 2, not seeded with SY MSC, demonstrates a gradual decline in 
counted cell numbers over a 7 days period followed by then, an increase of cell 
numbers.  
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Results demonstrated a gradual decline in the number of cells over a 10 day period, in 
both PRP donors, seeded with SY MSC, in addition a similar gradual decline in cell 
numbers was observed within PRP donor 1 scaffold, not seeded with SY MSC, and up 
to 7 days in PRP donor 2 scaffold, after which a small increase is observed. These 
results indicate that the cells being counted could indeed be another cell type, such as 
leukocytes, which can exists in PRP fractions (Amable et al, 2013) and not migrated 
SY MSC. This was further supported by the lack of cells counted initially, in the hPL 
scaffold, which was expected, followed by an increase in cells numbers after 7 days. 
Altogether, these data indicated that SY MSC migration though biological scaffolds are 
likely to be a slow process (after 7 days).  
 
To confirm this, a dual staining assay was set up, to label surface markers typically 
seen on MSC (CD73) as opposed to leukocytes (CD45), using this method of staining, 
accurate cell identification was achieved (section 5.12).  
 Dual staining of SY MSC and leucocytes with specific surface marker 5.12
primary antibodies 
Using PRP from one healthy individual, a 3D biological scaffold was created, and 
culture expanded SY MSC from one donor, were embedded into each scaffold, to 
ensure cells would be visualised once stained (section 3.13). The primary antibodies, 
namely anti-CD73 for MSC and anti-CD45 for leucocytes were used to stain the 
sectioned biological scaffolds. Due to the novelty of this type of dual stain, previous 
studies using a similar method were used as a guide (Letouzey et al, 2015), (see 
Figure 29).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 -­‐80-­‐	  
 
 
 
 
 
 
 
Figure 29: Dual staining of PRP scaffold embedded with cultured SY MSC. (A) 
Negative isotype control stained PRP scaffold (B) PRP scaffold stained with CD73 
primary antibody; embedded MSC appearing as large deep brown stained cells, 
highlighted in the inserted image.  (C) PRP scaffold stained with CD45 primary 
antibody; leukocytes present in PRP appearing as small red stained cells, highlighted 
in the inserted image. (D) PRP scaffold dual stained with CD45 and CD73 primary 
antibodies, leukocytes and SY MSC appearing as small red and large deep brown 
stained cells, respectively highlighted in the inserted image. Original magnification x 10 
(x 20 for inserts). 
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The above images provided a reference for how SY MSC within a biological scaffold 
look morphologically and phenotypically (large, CD73 positive cells). The investigation 
progressed to identify these cells by dual staining method following migration (section 
4.21), and to decide if indeed the cells being counted in sections 5.10 and 5.11 were 
migrated MSC, and not leukocytes present in PRP. Using PRP and PPP from one 
healthy individual, biological scaffolds were created. Culture expanded SY MSC from 
one donor, were seeded in a monolayer, and migration was allowed to take place over 
a 10 day period. Similar to previous migration study (section 4.14 and 4.20), scaffolds 
were sectioned and dual stained, and were visualised using the Olympus CKX41 light 
microscope. A control, PPP scaffold was created, which had no MSC seeded for 
migration, over a 10 day period, (see Figure 30). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  
 
 -­‐82-­‐	  
 
 
 
 
Figure 30: Dual staining of PRP and PPP scaffold following 10 days of migration 
with cultured SY MSC. (A) Negative control, PPP scaffold with cultured SY MSC. PPP 
scaffold dual stained with CD45 and CD73 primary antibodies, no CD45 stained or 
CD73 stained cells were identified, highlighted in the inserted image. (B) PRP scaffold 
with cultured SY MSC. PRP scaffold dual stained with CD45 and CD73 primary 
antibodies, small CD45 stained cells identified, with no CD73 stained cells observed, 
highlighted in the inserted image. (C) PRP scaffold with no cultured SY MSC. PRP 
scaffold dual stained with CD45 and CD73 primary antibodies, CD45 stained cells 
identified, with no CD73 stained cells observed, highlighted in the inserted image. 
Original magnification x 10 (x 20 for inserts)  
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The above images suggest that the cells counted in previous section of this study, 
investigating SY MSC migration through a relevant biological scaffold, were not SY 
MSC. The cells counted were likely leucocytes as they have been identified in similar 
quantities through scaffolds from both MSC seeded and non-seeded migrational 
studies, and been similarly stained with CD45 primary antibody. It is highly likely that 
previous section of this study (section 5.10 and 5.11) where cells being counted as 
migrated cells, were in fact leukocytes, and the MSC did not migrate through these 
biological scaffolds during chosen experimental timeframes (up to 10 days).  
 
In summary of SY MSC adherence and migration investigations, the results supported 
the hypothesis that SY MSC adhered and migrated towards biological scaffold; 
however, SY MSC migration through a biological scaffold did not occur in given 
experimental conditions. This suggests that SY MSC can be used for regeneration of 
the damaged articular cartilage; however, they may need to be placed in position of the 
articular defect, rather than being released and allowed to self-migrate towards and 
through a biological scaffold.  
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 Obtaining MSC from the synovium using the PAP brush in vivo 5.13
The following experiments aimed to demonstrate in vivo release of MSC from human 
synovium using the PAP brush. The focus of this part of the study was to use the 
knowledge gained from previous ex vivo experiments within an in vivo setting. MSC 
released from the synovium and those resident in SF were investigated using CFU-F 
assays. Flow cytometry was performed on cultured MSC (n=1 donor) as described in 
section 4.24, to demonstrate MSC phenotype. Trilineage potential of released and SF 
MSC was investigated using differentiation assays. Table 3 shows a patient overview.  
 
Table 3: An overview of patients participating in the in vivo PAP brushing study. 
Highlighted rows (n=5 donors) identify patients where culture expanded MSC were 
used for trilineage differentiation. 
 
 
 
Donor 
Age 
(yrs) 
Gender Injury Type 
 
Surgery 
 
23 25.4 F Left Knee Lateral Meniscal 
Tear 
Arthroscopic Left Knee Lateral 
Meniscal Tear Repair 
24 39.0 M Left Knee Anterior Cruciate 
Rupture 
Arthroscopic Left Knee Anterior 
Cruciate Rupture Repair 
25 40.4 M Right Knee Medial Meniscal 
Tear 
Arthroscopic Right Knee Medial 
Meniscal Tear Repair 
26 18.1 M Right Knee Lateral Meniscal 
Tear + 
Anterior Cruciate Rupture 
Arthroscopic Right Knee Lateral 
Meniscal Tear + 
Anterior Cruciate Rupture Repair 
27 19.3 M Left Knee Lateral Meniscal 
Tear 
Arthroscopic Left Knee Lateral 
Meniscal Tear Repair 
28 19.9 F Left Knee Lateral Partial 
Meniscal Tear 
Arthroscopic Left Knee Lateral 
Partial Meniscal Tear Repair 
29 52.0 M Left Knee Medial Partial 
Meniscal Tear 
Arthroscopic Left Knee Medial 
Partial Meniscal Tear Repair 
30 36.0 M Right Knee Anterior Cruciate 
Rupture 
Arthroscopic Right Knee Anterior 
Cruciate Rupture Repair 
31 29.5 M Right Knee Anterior Cruciate 
Rupture 
Arthroscopic Right Knee Anterior 
Cruciate Rupture Repair 
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 Obtaining MSC from the synovial fluid and synovium using the PAP brush 5.14
in vivo 
Patients with a median age of 29.5 years old (18.1-52.0) undergoing elective knee 
diagnostic or therapeutic arthroscopies participated in this study (n= 9 donors, Table 3).  
Three samples were collected from each donor, these consisted of 1) synovial fluid 
(SF), which in some cases was supplemented with saline, to aid in extraction; 2) 
Irrigation fluid, which was collected following the planned procedure (i.e. debridement) 
and 3) fluid collection after brushing of the synovium with the PAP brush (referred as 
post-brushing). All samples were transported within an hour of extraction to the 
research laboratory for processing in sterile conditions. SF with a mean volume of 
37.2mL (5-50mL), irrigation with a mean volume of 39.1mL (25-50mL), and post 
brushing with a mean volume of 53.1mL (50-70mL) were all collected in separate 
sterile container. Although all samples had differences in their volumes when received 
from the operating theatre, total number cells for each sample were normalized. This 
was achieved by centrifuging each cells sample into a pellet, and then re-suspending 
the pellet of cells in the same volume (10mL) of expansion media for each sample. 
CFU-F assays were performed on matched samples and data presented as colonies 
per sample, (see Figure 31) 
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Figure 31: Release of MSC from human synovium using in vivo, using PAP brush. 
(A) Examples of CFU-F assays for SF, irrigation and post brushing samples (n=1 
donor) stained with methylene blue. (B) CFU-F quantification data for the three 
arthroscopy samples: SF, irrigation and post-brushing. Data represented by median; 
(SF =432.5, irrigation = 12.5, post brushing = 470 colonies/sample) with upper and 
lower quartiles and minimum and maximum values (* = p<0.02, paired Wilcoxon test) 
(n=9 donors). 
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These CFU-F assays quantify MSC numbers from SF, irrigation and post synovial 
brushing, following an arthroscopy procedure and clearly demonstrated replacement of 
SF MSC, lost during irrigation in a standard arthroscopic procedure, with MSC from the 
post brushing phase, demonstrating no change (+0.09 fold increase) in 
colonies/sample. The PAP brush is not a device that is built to be used for such as 
procedure, thus one would expect an increase in released cell numbers when using a 
purpose made device to release SY MSC. Of particular note, the operating surgeon 
found this device unwieldy and difficult to manoeuver in the suprapatellar pouch during 
brushing.    
 Cell surface phenotype of culture expanded SF and post brushed cells 5.15
Flow cytometry was performed on culture expanded SF cells (n=3 donor) and post 
brushing released MSC (n=3 donor), passage 5-7, as described in section 4.24. 
Percentage of positive population for both phenotypically positive markers for MSC 
(CD73, CD90, CD105) and negative markers for MSC (CD14, CD19, CD34, CD45) 
consistent for expanded MSC (Jones et al, 2010; Harvanová et al, 2011; Baboolal et al, 
2014) were plotted (see Figure 32). 
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Figure 32: Surface phenotype of culture expanded SF and Post brushed cells. 
Percentage positive population for known positive and negative MSC surface markers 
for SF cells (n=3 donor) and post brushed cells (n=3 donor). Error bars represent 
standard deviation. 	  	  
The results demonstrated that both SF cells and those released from post synovial 
brushing, were phenotypically are MSC. 
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  Trilineage differentiation of cultured MSC obtained from human synovium    5.16
brushing in vivo study 
Investigation of SF MSC and SY MSC was undertaken using culture expanded cells 
passage 4-7, for trilineage differentiation. Osteogenesis was evaluated both 
qualitatively and quantitatively for five donors, undertaken in triplicate, as described in 
section 4.8.1. Alkaline phosphatase (an early osteoblast marker) staining at day 14 and 
alizarin red (demonstrating calcium deposits) at day 21 were performed. Total amount 
of calcium produced was quantified colorimetrically using a standard calcium assay kit 
for osteogenesis at day 21, (see Figure 33).  
 
Total calcium values were comparable to previous studies (Jones et al, 2010). No 
statistical significance between total calcium production from SF MSC and SY MSC 
was observed, suggesting that both cells have similar osteogenic properties.  
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Figure 33: Osteogenesis of in vivo released and cultured, donor matched SF MSC 
and SY MSC. (A) Examples of alkaline phosphatase and alizarin red staining, for SF 
MSC and SY MSC (n=2 donors) (scanned images). (B) Total calcium/well (µg/mL) 
production for SF MSC and SY MSC (n=5 donors). These findings demonstrate 
acceptable osteogenic capabilities. 
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Adipogenesis was evaluated both qualitatively and quantitatively, using cultured SF 
MSC and SY MSC for five donors, as described in section 4.8.2. At day 21, Oil red-O 
staining was performed; showing lipid-containing vesicles produced by the MSC. Nile 
red-DAPI ratio was used to quantify adipogenesis. Large Nile red:DAPI ratios denote 
high lipid concentration per cell, (see Figure 34). 
 
Adipogenic potential was demonstrated from SF MSC and SY MSC. These results 
were comparable to those observed previously in this study and other studies (Aldridge 
et al, 2013). Lipid filled vesicles was observed using oil-red-O staining, and ratios of 
Nile red against DAPI, displayed good yields of adipogenesis. No statistical 
significance was observed for total lipid production between SF MSC and SY MSC, 
implying that both cells have similar adipogenic properties.  
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Figure 34: Adipogenesis of in vivo released and cultured, donor matched SF MSC 
and SY MSC. (A) Oil red-O stain at x20 magnification of SF MSC and SY MSC (n=1 
donor). (B) Quantification of adipogenesis using Nile:DAPI ratio, mean values of 
triplicates. Error bars represent standard deviation (n=5 donors). These findings 
demonstrate acceptable adipogenic capabilities. 
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Chondrogenesis was evaluated both qualitatively and quantitatively as described in 
section 4.8.3. Chondrogenic pellets were cultured for 21 days, for both SF MSC and 
SY MSC. Quantitative analysis was performed using the Blyscan™ s-GAG assay kit for 
five donors (in triplicate for each donor), at day 21, and three donor cultures were used 
for qualitative assay (see Figure 35). 
 
Chondrogenic potential was demonstrated from the SF MSC and SY MSC. Both 
quantification and qualification was comparable to those observed in previous studies 
(English et al, 2007; Jones et al, 2010). No statistical significance between total GAG 
production from SF MSC and SY MSC was observed, implying that both cells types 
have similar chondrogenic properties.  
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Figure 35: Chondrogenesis of in vivo released and cultured, donor matched, SF 
MSC and SY MSC. (A) Chondrogenic pellets stained with toluidine blue, showed GAG 
stained in purple, and fibrous tissue stained blue (n=1 donor). (B) Total GAG content in 
µg/pellet for each sample following papain digestion (n=5 donors). Data represented by 
mean value of the triplicate assays (total GAG content) per samples, for each donor. 
These findings demonstrate acceptable chondrogenic capabilities. 
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The overall results for trilineage differentiation of in vivo released (using PAP brush) SF 
MSC and SY MSC demonstrated that resulting cultures do indeed show trilineage 
differentiation capabilities, both qualitatively and quantitatively. In three out of five 
donors, SY MSC demonstrated overall higher levels of GAG and lipid production 
compared to resident SF MSC. Calcium production was similar between both MSC 
sources. In summary, experiments demonstrated encouraging results in terms of in 
vivo released SY MSC and their use for cartilage defect repair.  
 
As previously mentioned, the design of the PAP brush is not built for the purpose of 
arthroscopy, hence the consideration of the purpose made device that would further 
increase and augment SY MSC numbers. For this reason, a tailored synovial MSC 
releasing device was developed based on prototype C8 (see Figure 15), with design 
opinions from expert orthopaedic surgeons who would use this device during an 
arthroscopic procedure, thus providing in depth knowledge, of device design 
requirements. The following set of experiments substituted the PAP brush with the 
purpose built device; however, maintained the same experimental protocols, allowing 
both devices to be relatively compared.  
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 Obtaining MSC from the synovium using a purpose made device to release 5.17
SY MSC in vivo 
The following experiments aimed to demonstrate in vivo release of MSC from human 
synovium using a purpose made device (based on prototype C8, see Figure 15). 
Quantification of released cells and those originating within the synovial fluid, were 
compared, to consolidate the hypothesis that MSC lost during the irrigation phase of an 
arthroscopy procedure can be replaced using a purpose made device that releases SY 
MSC. Patients with a median age of 33.7 years old (22.0-53.7) undergoing elective 
knee diagnostic or therapeutic arthroscopy participated in this study (n= 10) Table 4.  
Similar arthroscopy procedure to that described in the previous section 4.22 was used, 
with the PAP brush being substituted with a purpose made device. Three samples 
were collected from each donor, these consisted of 1) SF, 2) Irrigation fluid, and 3) post 
brushing of the synovium samples. SF was collected, with a mean volume of 38.7mL 
(5-50mL), the irrigation sample was collected, with a mean volume of 40.5mL (25-
50mL), and the post brushing sample was collected, with a mean volume of 53.4mL 
(50-70mL), all samples were collected in a sterile container and transported within an 
hour of extraction to the research laboratory for processing in sterile conditions. Similar 
to the previous experiment using the PAP brush, all samples in this experiment had 
different initial volumes, total number cells within each sample were quantified by 
centrifuging each sample and re-suspended in 10mL of expansion media. CFU-F 
assays were performed on matched samples and data presented as colonies per 
sample (section 4.22 and 4.25), (see Figure 36). 
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Table 4: An overview of patients participated in the in vivo purpose built synovial device 
brushing study. 	  	  
 
 
 
 
 
 
 
 
 
 
Donor 
Age 
(yrs) 
Gender Injury Type Surgery 
32 41.3 M Right Knee Medial 
Osteochondral Fragment + 
Medical Meniscal Tear 
Arthroscopic Right Knee Medial 
Osteochondral Fragment + Medical 
Meniscal Tear Repair 
33 26.2 M Right Knee Medial Meniscal 
Tear + 
Anterior Cruciate Rupture 
Arthroscopic Right Knee Medial Meniscal 
Tear + 
Anterior Cruciate Rupture Repair 
34 45.3 F Left Knee Medial Condylar 
Lesion  
Arthroscopic Left Knee Medial	  
Chondroplasty  
35 27.1 M Left Knee Medial Condylar 
Lesion 
Arthroscopic Left Knee Medial 
Chondroplasty 
36 22.0 M Left Knee Partial Lateral 
Meniscal Tear 
Arthroscopic Left Knee Partial Lateral 
Meniscal Tear Repair 
37 25.2 M Unknown Right Knee Injury Diagnostic Arthroscopic of Right Knee  
38 53.7 M Right Knee Medial Condylar 
Lesion + Medical Meniscal 
Tear 
Arthroscopic Right Knee Medial 
Chondroplasty + Medical Meniscal Tear 
Repair 
39 25.4 M Left Knee Anterior Cruciate 
Rupture + Medial Meniscal 
Tear 
Arthroscopic Left Knee Anterior Cruciate 
Rupture + Medial Meniscal Tear Repair 
40 40.3 M Left Knee Lateral Collateral 
Ligament Rupture 
Arthroscopic Left Knee Lateral Collateral 
Ligament Rupture Repair 
41 42.1 M Unknown Right Knee Injury Diagnostic Arthroscopic of Right Knee 
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Figure 36: Release of MSC from human synovium using in vivo, a purpose built 
device. (A) Representative examples of CFU-F assays for SF, irrigation and post 
brushing samples (n=1 donor). (B) This demonstrated a reduction of MSC during 
irrigation, and a replacement of MSC following synovial brushing. Data represented by 
median; (SF =797.5, irrigation = 426, post brushing = 6075 colonies/sample) with upper 
and lower quartiles and minimum and maximum values. Statistical significant increase 
of MSC numbers between SF and post-brushed groups observed with a 6.6 fold 
increase (* = p<0.05, paired Wilcoxon test). (n= 10 donors) 
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The results from section 5.13 demonstrated that MSC were released from the 
synovium during an arthroscopy procedure in which a PAP brush was used. The 
results from section 5.13 also demonstrated a statistically significant loss in MSC 
numbers from SF to irrigation. There was also a statistical significant increase in MSC 
number when comparing irrigation with post-brushing. Comparing MSC numbers 
between SF and post brushing cell numbers, we observed no change (+0.09 fold 
increase). Trilineage differentiation assays (section 5.16) demonstrated that MSC 
found within the SF and those released during synovial brushing were similar in 
respect to osteogenic, adipogenic and chondrogenic capabilities.  
 
It must be noteworthy that the PAP brush is not a device built to be used in an 
arthroscopy procedure, thus a larger increase would be expect in released cell 
numbers when using a purpose made device to release SY MSC. Indeed, this was 
observed in section 5.17, were the purpose made device was used in vivo, a 
statistically significant increase in number of MSC from SF to post brushing, 
demonstrating a 6.6 fold increase in colonies compared to SF *see Figure 36). Indeed 
when comparing MSC released from both PAP and the purpose made device, we 
observed a 12-fold increase in MSC numbers. Although the results were from two 
separate sets of data, and have been implicitly compared as both in vivo MSC brushing 
protocol was followed for both. The only significant difference between the two in vivo 
experiments was that of the device used intra-operatively. (see Figure 37).  
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Figure 37: Comparison of released MSC in vivo, using a PAP and purpose built 
device. (A) Representative examples of CFU-F assays for SF, irrigation and post 
brushing samples (n=1 donor). (B) Demonstrates a 12 fold increase of MSC using the 
purpose built arthroscopy device compared to PAP brush. Data represented by 
median; PAP = 470 colonies/sample (n=9 donors) and purpose built arthroscopy 
device = 6075 colonies/sample (n=10 donors) with upper and lower quartiles and 
minimum and maximum values.  
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Cartilage destruction is a key feature of OA (section 1.4 and 1.5) with chondrogenesis 
playing a key role in providing a supply of GAG that is needed for cartilage 
homeostasis and repair. The findings in the present studies endorse, the use of SY 
MSC as a potential source of cells for cartilage repair, and as observed above, SY 
MSC can be released in vivo in high numbers. In summary, this study supports the 
hypothesis that, a purpose made device to release SY MSC, would not only replace 
lost MSC, but would rather augment their number. These cells, in the correct 
mechanical and correct chondrogenic environment could contribute to cartilage 
regeneration in injured arthritic knee joints.  	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Chapter 3 
6. Discussion  
 Review of aims and hypothesis 6.1
The overarching aim of this study was to use the philosophy that endogenous MSC 
could be used to regenerate knee joint articular cartilage. The strategy of using a novel 
purpose built device that is able to release large numbers of endogenous MSC, has 
been developed within this study. These outcomes provide a new cost effective 
concept of MSC obtainability towards new proof of concept studies in OA.  
The first part of this study was focused on developing a brushing device that released 
MSC rather than trap them within its bristles.  Differing design prototypes were used to 
release MSC from the synovium under ex vivo porcine and human tissue conditions. 
MSC were expected to develop from released cells of the synovium tissue (De Bari et 
al, 2001), and a standard CFU-F assay was used in quantification. This assay is 
commonly used to measure the MSC (Mochizuki et al, 2006) in the synovium and other 
tissues, such as synovial fluid and bone marrow MSC (Jones et al, 2004) and cardiac 
MSC (Chong et al, 2011).  Using DNA analysis, released cells from the synovium and 
those trapped within the device bristles were quantified, which aided in the 
development of a purpose made device to release SY MSC. While DNA analysis was 
used as an indicator of cellular material released from the synovium and also trapped 
within the prototypes bristles, CFU-F assay was used to measure MSC released from 
the synovium. Finally, released MSC from synovial tissue were expanded in culture 
and expected to demonstrate typical trilineage differentiation abilities (English et al, 
2007; Baksh et al, 2007; Solchaga et al, 2011; Aldridge et al, 2013)  
The second part of this study investigated natural biological scaffolds, and their effects 
on the adherence and migration of SY MSC. Once MSC are released intra-articulary, 
the role of endogenous factors that might bring released MSC to the regions of 
cartilage damage is desirable. Posited methods to achieve this include either MSC 
loading onto a biological scaffold and then placed into defect or by adherence and 
migration to naturally formed scaffolds such as a microfracture.  	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The types of scaffolds tested were based on a fibrin clot, commonly used in cartilage 
tissue engineering studies (Stafford et al, 2011; Kim et al, 2015), without or with the 
addition of platelet-based. The latter were added based on the evidence that hPL or its 
predecessor PRP contain a cocktail of growth factors (GF) and inflammatory 
mediators, potentially effective in cartilage repair (Xie et al, 2014). It was hypothesized 
that first, SY MSC would adhere to biological scaffolds and second, that scaffolds 
containing PRP or hPL would demonstrate favorable MSC migration properties. This 
was based on previous literature showing the high content of GF in hPL (Radtke et al, 
2014) and PRP (Mollon et al, 2013; Van Pham et al, 2013; Ornetti et al, 2016) that aid 
in articular repair.  
 
The third part of this study was to use the knowledge gained from the ex vivo study, 
including both PAP brush and the chosen best performing purpose-made brushing 
device (C8), to be used within an in vivo surgical setting. The aim of which was to 
release enough SY MSC that would replace (or augment numbers) of SF MSC, lost 
during the irrigation phase of an arthroscopy procedure. This would potentially create 
an environment to aid in the repair of an arthritic knee. CFU-Fs were expected to 
develop from released cells of the synovium tissue. In this work, the released cells had 
a SY MSC nature and proliferated and demonstrated typical trilineage differentiation 
capabilities. Furthermore, cultures from released synovial were confirmed 
phenotypically as MSC, using flow cytometry based on ISCT phenotype used in 
previous studies (Jones et al, 2010; Harvanová et al, 2011; Baboolal et al, 2014). It 
was hypothesized that a purpose made device to release SY MSC, would release 
more MSC than the PAP brush, and would therefore better replace lost MSC following 
irrigation phase of an arthroscopy. 
 Obtaining MSC from the synovium ex vivo  6.2
Previous studies (De Bari et al, 2001; Sakaguchi et al, 2005; Fan et al, 2009; 
Harvanová et al, 2011; Ogata et al, 2015) have shown that the synovium holds great 
potential in providing an abundant endogenous supply of SY MSC. It was expected 
that mechanically dislodging MSC from the synovial lining, potentially increased the 
number of SY MSC within the knee cavity, without the need of culture expansion.  
 
In these experiments CFU-F assay was used as a tool to measure MSC numbers, 
(Jones et al, 2010). Supplementary quantification methods were used to provide 
quicker results for the total released versus trapped cellular content, such as phenol-
cholorform DNA extraction. This method removes DNA from the nuclei of cells. The 
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DNA content is measured using a NANO-drop spectrophotometer. However, this 
method provided quantification of all cellular material released or trapped, and was not 
specific to MSC, therefore was used as an indication for prototype development. A 
series of device prototypes, in which bristles were positioned in a series of 
configurations, aimed at maximal cell release and minimal cell trapping was tested. For 
example C1 consisted of thin multiple soft bristles, whereas C2 was designed with 
thicker more ridged bristles (see Figure 15). The focus was to optimize the released 
number of cells from the synovium, whilst attempting to reduce the number of cells 
trapped within the bristles, these were compared to the PAP brush (control).  
 
During the initial phase of device development, using human synovium, with CFU-F 
quantification, MSC release using a purpose build device was achieved. However, in 
the devices used, no statistical significance was observed, between numbers of MSC 
released. Although C2 and C4 demonstrated a marginally increased released numbers 
of MSC, in terms of CFU-F assays, compared to other device designs (see Figure 17). 
In addition, comparing number of trapped cells against released cells, two devices C2 
and C4 were tested. Device C2 did show statistically significant number of cells were 
trapped more then released in ex vivo excised porcine synovium experiments (see 
Figure 16). This information was used to further develop devices C6 and C7.  
 
Device C6 was developed using combination of design features from C2 and C4, both 
of which releasing marginally higher MSC compared to other device prototypes. C7 
was a new design prototype that coupled the bristles shaped design feature of C2 with 
the diamond shaped orientation of C4. The results revealed no statistical significant 
difference between these two device prototypes during ex vivo excised porcine and 
human synovium experiments (see Figure 18 and Figure 19).  
 
The final phase of device development was to use the diamond shaped configuration 
as seen in C7, with the rationale that cell release will be improved if multiple brushing 
directions were used. In addition, spacing between bristles was increased, in an 
attempt to allow for a reduction in trapped cells. When C8 was compared to the PAP 
brush, in regards to MSC release, no statistically significant difference in released MSC 
numbers observed in ex vivo, 1 cm2 excised human synovium was observed. (see 
Figure 20a). However, improvements had been observed with these new designs, 
which were demonstrated by a reduction of cell trapped, compared to released, when 
used to brush ex vivo 1 cm2 excised porcine synovium (see Figure 20b). 
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Although results from both porcine and human synovium ex vivo experiments, 
demonstrated overall no statistical significance, it felt sensible to recognize, that the 
device used during an arthroscopy procedure should be a purpose built device, suited 
for this type of surgery.  
 
Trilineage differentiation potential of ex vivo cultured SY MSC, was satisfactory 
demonstrated. Osteogenesis was assessed using recognised analysis techniques 
(Pittenger et al, 1999; Jones et al, 2002; English et al, 2007). Total calcium production 
over 21 days of osteogenic induction was quantified colorimetrically using a standard 
calcium assay kit (English et al, 2007). Alkaline phosphatase (ALP) activity, an early 
marker of osteogenic progression (Tsai et al, 2009), which is peaked at the initial 14 
days of differentiation, was confirmed by staining with Fast RR blue salt. Finally, after 
21 days calcium deposits were stained using alizarin red dye which evaluates calcium-
rich deposits produced by osteoblasts (Pittenger et al, 1999). Qualitative and 
quantitative analysis demonstrated tripotential MSC released from all six donor 
synovium samples (see Table 2); however, total calcium values (see Figure 21) were 
less than those described in other studies using SF MSC from arthritic joints (Jones et 
al, 2004). A possible explaining for this could be due to the synovium used during ex 
vivo experiments was from donors of an average age of 71.25 years. Age has been 
shown to a down-regulate MSC osteogenesis (De Girolamo et al 2009; Beane et al, 
2014).  
 
Adipogenesis was assessed using recognised analysis techniques in which fat cells 
were stained with oil red-O (Sekiya et al, 2012; Aldridge et al, 2013). Adipogenic 
potential was demonstrated for all cultures in the ex vivo experiments (see Figure 22). 
Both staining and fat quantification was comparable to those observed in previous 
studies (Aldridge et al, 2013), which state Nile red/DAPI ratios of 2-12, compared to 2-4 
found in this study. These ratios of Nile red against DAPI, displayed good levels of 
adipogenesis and lipid filled vesicles were present using oil-red-O staining.  
 
Chondrogenesis was assessed using a recognised pellet culture model, of ex vivo 
MSC released from the synovium (Jones et al, 2002; English et al, 2007). 
Chondrogenic potential was demonstrated using GAG measurements as well as 
sectioning of pellets followed by staining with toluidine blue which stains cartilaginous 
extracellular matrix purple, and fibrous tissue blue (see Figure 23). Although using a 
different GAG quantification kit from that in previous studies, comparable results of 
GAG content were demonstrated (English et al, 2007) which state values of 2.5-
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10µg/pellet, compared to 1-9 µg/pellet found in this study. Pellet staining also 
demonstrated equivalent results (Jones et al, 2010; Segawa et al, 2009; Ogata et al, 
2015).  
 
Donor-to-donor variation was observed in the chondrogenic assay. A possible 
explanation for this difference could be due to variation in levels of synovial 
inflammation observed between donors, which is known to effect chondrogenesis 
(Jones et al, 2010). However, overall chondrogenic results in this study were 
satisfactory in demonstrating chondrogenesis.  
 
The overall results for trilineage differentiation of ex vivo released MSC demonstrated 
that resulting cultures did indeed show trilineage differentiation capabilities, both 
qualitatively and quantitatively. These findings occurred despite the robust mechanical 
release of MSC. 
 Adhesion and migration of MSC with relevant biological scaffolds 6.3
The interaction of culture expanded SY MSC when allowed to attach, migrate towards 
and through biological scaffolds was tested. One of the scaffolds tested was made 
from whole blood, and was supposed to mimic natural scaffold formed as a result of 
microfracture. Currently microfracture (section 1.7) is used as a treatment option for 
isolated articular injuries. It is believed that following a microfracture BM MSC and the 
constituents of the blood, namely platelets, from the sub-chondral bone migrate into a 
defect, and over time differentiate and mature into fibrocartilage (Steadman et al, 2002; 
Neumann et al, 2008; Chen et al, 2011; McIlwraith et al, 2011; Haughom et al, 2014) If 
released SY MSC could attach to such a naturally formed scaffold, this would point 
towards a possibility of using synovial brushing arthroscopy in conjunction with 
microfracture. The rationale for testing the effects of PRP was based on available 
clinical treatments showing PRP intra-articular injection to be beneficial compared to 
placebo (Patel et al, 2013), this could be possibly due to the chemo-attractive and 
chondro-inductive substances present in PRP (Mollon et al, 2013;.Zhu et al, 2013).  
Should stronger SY MSC migration toward PRP scaffold be seen, this would point 
towards a directed delivery of PRP scaffold in a defect area, in the same procedure as 
synovial brushing. Overall, this part of the study was to observe the interactions 
between SY MSC and these biological scaffolds that are potential useful adjunct to 
arthroscopic SY MSC therapy. All biological scaffolds were based on clots that were 
additionally supplemented with:  a) whole blood scaffold (resembling a microfracture, 
section 1.7), FG  (described as an effective scaffold for focused MSC delivery) (Kim et 
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al, 2015), b) Platelet rich plasma scaffold (known for their delivery of chondro-inductive 
growth factors) (Van Pham et al, 2013; Mollon et al, 2013; Ornetti et al, 2016) and c) 
human platelet lysate scaffold (rich source of growth factors from thermally burst 
platelets) (Radtke et al, 2014). 
 
These results demonstrated that SY MSC adhesion to the aforementioned three 
biological scaffolds was rapid, with more than 65% attachment occurring within 30 
minutes. In addition, it was shown that no significant variation occurred on adhesion 
times, when SY MSC cultures from three different donors were used to adhere to a FG 
scaffold, suggesting that adhesion of MSC is non-specific to currently available scaffold 
types. Experiments investigating MSC migration towards biological scaffolds, 
demonstrated better migration at 24 hours compared to 4 hours when using hPL, which 
is consistent with a pervious study (Marrazzo et al, 2016) that showed optimal 
migration period to be 24 hours when using hPL. In addition, both PRP and hPL 
scaffolds induced better migration of SY MSC compared to negative controls, 
suggesting that human platelets do indeed release constituents that improve migration 
(Leotot et al, 2013; Zhu et al, 2013). Within a clinical setting, platelet based biological 
scaffolds could be used a method of delivering MSC directly to the defect.  
 
Given SY MSC are able to migrate towards and attach to a biological scaffold, it would 
be advantageous if they could evenly migrate through the scaffold and populate to 
whole area with chondrogenic precursor cells. In an experimental conditions used in 
this study, SY MSC migration through a 3D biological scaffold was not observed, this 
was demonstrated by using dual stain technique with primary antibodies specific to 
MSC (CD73) and leucocytes (CD45). Previous studies have shown SY MSC migration 
through a synthetic collagen-based 3D scaffold laced with growth factors transforming 
growth factor β3 (TGF-β3) or human stromal derived factor 1β (SDF-1β) (Mendelson et 
al, 2011).  It is likely that scaffold pore size between this and Mendelson et al study 
were different and that they may have a strong effect on MSC migration through a 3D 
scaffold (Murphy M, et al. 2010). The biological scaffolds used in this study potentially 
could have differing structural properties amongst each other, for example the matrix 
structure possibly could be too tight in a PRP scaffold, therefore creating small pore 
sizes that are too small to allow for MSC to migrate through, and could be a reasonable 
explanation for lack of migration. This experiment would require further work for 
example, by testing biological scaffolds that are supplemented with constituents that 
could alter its matrix layout, for example, a polymer creating a layered bed of fibres, 
thus modifying MSC migration through the scaffold, or another option may be to use a 
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collagen or GAG scaffold embedded with MSC released from brushing, in an 
attempted to keep the materials homogenous (Lawrence B, et al. 2008; Meng X, et al. 
2014).   
In summary these results strengthened the hypothesis, that released SY MSC could 
adhere to and migrate towards platelet based biological scaffolds, which can be used 
for regeneration of the articular cartilage damaged, potentially removing the need to 
create a microfracture.  
 Obtaining MSC from the synovial fluid and synovium using the PAP brush 6.4
in vivo 
The PAP brush is a medical device that is used in human as a method of harvesting 
cells from superficial, deep serosal or mucosal surfaces (Al-Abbadi et al, 2011). Its 
main use is within a gynecological setting, where it is used to gather cells for 
cytopathology. In this study we used the concept of the PAP brush, and implemented it 
towards designing a brush that would release SY MSC in vivo. The CFU-F assays 
were used to quantify cells from SF, irrigation and post synovial brushing (Jones et al, 
2010). These results demonstrated a statistically significant replacement of SF MSC, 
lost during irrigation with SY MSC released during post synovial brushing, in a standard 
arthroscopic procedure. Comparing MSC numbers between SF and post-brushing, 
comparable results were observed; however, it must be noted that the PAP brush is 
not designed for this type of procedure, thus an increase in released synovial cell 
numbers when using a purpose made device was expected. In addition, MSC from the 
SF, irrigation and post synovial brushing fraction, did adhere to plastic and formed 
colonies, which is consistent with MSC; however, to further verify these cells as being 
MSC, flow cytometry was used on selected cultures.  
 
Flow cytometry was performed on culture expanded SF cells (n=3 donors) and culture 
expanded post synovial brushing released cells (n=3 donors). As stated previously 
(Dominici M, et al. 2006) , flow cytometry is an established method of confirming MSC 
identify of plastic adherent fibroblastic cultures. Previous studies that have 
characterized SF-MSC and SY-MSC using markers for both phenotypically positive 
(CD73, CD90, CD105) and negative (CD34, CD19, CD45, CD14) for expanded MSC 
(Jones et al, 2010; Harvanová et al, 2011; Baboolal et al, 2014). Surface markers 
CD73 and CD90, are well-recognised MSC markers, and were uniformly expressed in 
all cultures. Expression of CD105 in both SF and post brushing cells, is significant due 
to it being suggestive of the cells responses to chondrogenic induction (English et al, 
2007). As previously mentioned, SF MSC and SY MSC share similar phenotypes, and 
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this was found to be the case in this study, thus further suggesting that these cells may 
be from a similar source. However, cell surface markers expression is not stable, and 
conditions such as inflammation MSC can potentially alter their phenotype (Lv et al, 
2014), or culture expansion can indeed make MSC phenotype similar. For this reason, 
further investigation of SY MSC and SF MSC from donor matched, non-cultured 
samples, would aid in the characterization of these cells.   
 
Trilineage differentiation of in vivo cultured SY MSC, was satisfactory demonstrated. 
Osteogenesis in all five donors showed acceptable levels of ALP, alizarin red and 
calcium deposits Adipogenic potential was also demonstrated for cultures from the 
cells released, and were comparable to those observed in previous studies (Sekiya et 
al, 2012; Aldridge et al, 2013). Chondrogenic potential were comparable to results 
observed in previous studies (Jones et al, 2002; English et al, 2007; Segawa et al, 
2009; Ogata et al, 2015). In all three domains (CFU-F assays, phenotyping and 
trilineage differentiation) this study demonstrates these cells to have MSC capabilities.  
 
In summary, these experiments demonstrated encouraging results in terms of in vivo 
released SY MSC. In additional both SF MSC and SY MSC have similar osteogenic, 
adipogenic and chondrogenic capabilities, thus further supporting the hypothesis for 
SY MSC use as a potential source of MSC for cartilage repair.  
 
The next part of the thesis brought together the knowledge gained from results of MSC 
release, using device prototypes and PAP brush, and was coupled with design 
opinions from orthopaedic surgeons. This resulted in a tailored synovial cell-releasing 
device being developed. The design feature encompassed a robust design that is 
personalized to this type of procedure. These features of the device included a long 
robust arm, which can enter easily through an arthroscopic port for robust brushing of 
the suprapatellar pouch. The material used was an inert poly-ethylene, in addition the 
brush head was angulated at 30 degrees on an extended arm allowing for control when 
brushing the synovium.  	  
 Obtaining MSC from the synovium using a purpose made device to release 6.5
SY MSC, in vivo 
A similar process was used to previous in vivo experiments described in section 4.22 to 
release MSC during an arthroscopy procedure; however, in this part of the study the 
PAP brush was replaced with a purpose made device to release SY MSC (based on 
prototype C8, see Figure 15). CFU-F assays were used to quantify cells from SF, 
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irrigation and post synovial brushing and demonstrated a statistical increase in number 
of cells from SF to post-brushing. In addition we observe a 12 fold increase of MSC 
when using the purpose built device compared to the PAP brush (see Figure 37). This 
further supports the hypothesis that SY MSC can be successfully released from the 
lining of the synovium to augment MSC numbers within the joint cavity, during an 
arthroscopy.  With an increase number of MSC released post brushing compared to SF 
cells, this would potentially set an environment where an amplified number of 
endogenous MSC would be available to regenerate cartilage defects.  
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 Study Limitations  6.6
This study uses a novel approach to release joint resident MSC, providing a new 
approach for healthcare providers toward the assessment of endogenous MSC 
towards articular cartilage repair. Due to the studies’ originality the difficulties faced 
were unique. During device prototype development, there were some delays in phase 
2 prototypes production. This had an effect on the number of samples used for 
quantification, as some patients that could be included in the study, were unfortunately 
not recruited, three donors were lost due to this delay.  
 
Using human synovial tissue from patients with advanced OA resulted in large 
variations in consistency of the synovium. The synovial sizes that were harvested were 
varied and depended on the individual’s anatomy. It was therefore difficult to section 
the synovial sample so that all the device prototypes could be tested. This resulted in 
differing donor numbers for CFU-F assays.  
 
The study on adherence and migration using biological scaffolds was limited, as 
conditions did not truly replicate typical in vivo environments. It would have been ideal 
if experiments could have recreated the dynamic movements of MSC within the joint, 
alongside the mechanical forces. In addition SF effects, due to its viscosity (Baboolal et 
al, 2014) were not replicated, and could have implication on adherence and migration. 
 
Biological scaffolds made from whole blood (WB) were used in the study, due to its 
resemblance to clots formed during a microfracture. However, unlike microfracture, WB 
does not have bone marrow MSC (BM MSC) present. In order to create an ex vivo 
microfracture model, it would have been useful to have BM MSC embedded within a 
WB scaffold, to assess potential variability. While the presence of embedded BM-MSC 
would not likely affect SY-MSC attachment, it might improve on the quality of cartilage 
repair.   
  
The biological scaffolds were used to assess MSC migration through 3D structures did 
not demonstrate migration of SY-MSC through these scaffolds. Constructing the 
various biological scaffolds was difficult, due to the inconsistency in the scaffold 
formation. This could have been due to many factors, for example variations in the 
PRP preparation methods, which regularly provide differing platelet and leukocyte 
quantities, and is quite a common outcome in other studies (Amable et al, 2013; Araki 
et al, 2012; Lee et al, 2013; Van Pham et al, 2013).   
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Due to the fragility of scaffold constructs, it led to difficulties in the sectioning of the 
scaffold. Once stained, counting the cells within the scaffold was also difficult, despite 
counting several sections for the better statistical averages. 
 
Further work is needed to understand migration of MSC within a scaffold; for example, 
by labelling MSC with specific fluorescent tracker dyes (Baboolal T et al, 2016; Zou L, 
et al, 2013) that would clearly identify MSC. In addition, the difficultly with biological 
scaffold sectioning could also be addressed by use of such fluorescent imaging 
techniques using a confocal microscope. Changing scaffolds’ consistency to observe 
potential effects of pore sizes on migration, for example by using differing 
concentration of fibrinogen, maybe useful in determining a consistent scaffold for MSC 
migration.   
 
These results can be used as an indication to adopt an approach of cartilage 
regeneration using native MSC, such as releasing SY-MSC and then loading them into 
a scaffold to be directly placed into the defect; this could negate the need to rely upon 
natural MSC migration and homing into defects. This can be achieved by capturing 
released SY-MSC using irrigation of the cells into a reservoir, then a in theatre 
centrifugation system to pellet the SY MSC. SY MSC can be then loading in to the 
defect with a PRP scaffold using a dual syringe system (Haleem M, et al. 2016).  For 
more advanced OA, there is evidence that without scaffolds, MSC can adhere to sites 
of injured cartilage, so the augmentation of MSC in that setting might naturally lead to 
good joint repair by mechanisms not dependent on scaffolds (Baboolal T, et al 2016). 
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 Clinical relevance and future clinical directions 6.7
Future proof of concept studies that increased numbers of MSC within the knee joint 
cavity may aid in repair, and reduce pain that is indicated by better patient pain 
outcomes are due to start in 2017. These will employ clinical outcomes including the 
visual analog score (VAS), or the Western Ontario and McMaster University 
Osteoarthritis Index (WOMAC) in clinical practice (Lamo-Espinosa JM, et al. 2016). 
Autologous MSC are an appealing source of MSC cells due to their lack of tissue 
rejection or cross infection; however, the consistent low yields of cells, and the 
necessity to culture expand these cells, coupled with a two stage surgical procedure, 
will ultimately not be cost effective. This emphasises the need for a technique that 
provides good yields of autologous MSC that are obtained cost effectively, and uses 
only minimal number of surgical interventions.  
 
This study demonstrates significant increase of SY MSC released from the synovium 
using a purpose made device. There was a 12 fold increase in the number of SY-MSC 
released, when the surgeon uses the purpose made device compared to PAP brush. In 
summary, this study demonstrates a novel device that can be used cost effectively by 
healthcare providers to augment the number of autologous joint resident MSC within 
the knee, without the need to culture expand MSC. In addition this process can be 
undertaken within the time limits of current arthroscopy procedures, which negates the 
requirement for extra anesthetic	   time. Knowing that cells can adhere rapidly and 
migrate well towards a scaffold, the augmentation of SY MSC can be used in 
conjunction with, but not limited to, procedures such as microfracture.  Post-surgical 
rehabilitation is also not affected, as patients usually are non-weight bearing following 
many arthroscopy procedures for times that are beyond what is taken for released cells 
to adhere and migrate.  	  
The release of MSC from the synovium, using the purpose made device, can be used 
in combination with existing therapeutic procedures. The current treatment of articular 
disease such as OA (shown below and in section 1.6) could be amended to include 
treatment with endogenous autologous SY MSC (Table 5). 
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Table 5: An overview of current treatment options for OA, with the addition endogenous 
autologous SY MSC release treatment.  	  
	  	  
For isolated articular injuries, microfracture (section 1.7) is a therapeutic procedure 
used, that relies on BM MSC to fill the defect, repairing the cartilage with fibrocartilage. 
As BM MSC are relatively low in numbers (Peng et al, 2008), these could be 
augmented with the released SY MSC allowing more cells to be available for repair. A 
further enhancement of an arthroscopic microfracture can be developed, using 
biological scaffolds, such as PRP sourced from the patients’ own blood. During 
arthroscopy, where an isolated defect is identified and debrided, and the synovium 
brushed with the purpose built device to release SY MSC, the region can have a 
biological scaffold applied to it with the aid of the dual-syringe system loaded with 
released SY MSC. This would potentially have three benefits; 1) it will use endogenous 
autologous MSC; 2) it will withhold the use of drilling holes within the already damaged 
articular region, allowing for less site morbidity and 3) it will focus chondro-inductive 
agents (i.e. autologous PRP) directly at the site of injury, this potentially would create 
better quality cartilage. In addition to improving the outcome for the patients, this new 
procedure would also be considered advantageous for the healthcare provider, as it 
would be cost effective, as this new technique requires no externally sourced MSC. 
However, there may be drawbacks with this method, for example, usual arthroscopy 
operating times may be extend due to biological scaffold preparation times. Coupled 
with the process of SY MSC embedding into the scaffold this could drastically increase 
operation times, which would inevitably increase costs. To overcome this, a more 
simple protocol could be developed where a biological scaffold such as PRP, would be 
prepared, prior to surgery, using the patient own blood source. Following debridement 
of the defect, the scaffold can be applied to the defect, and then the synovium brushed, 
so that SY MSC can be augmented within the cavity. Although this would not focus the 
SY MSC to the sight of injury, this technique would be a quicker one-stage surgical 
procedure, thus, potentially cost saving.    
Simple Analgesia 
Grade&0& Grade&1& Grade&2& Grade&3& Grade&4&
No treatment 
Intra-articular corticosteroid injection 
Osteotomies  
or  
Partial Knee replacements  
Total Knee Replacements  
Arthroscopy-lavage and debridement  
Endogenous autologous  
SY-MSC release 
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As shown in this thesis, natural migration of released SY MSC through biological 
scaffold may be difficult (section 5.10-5.12). Based on these findings one can propose 
one further advance of the above procedure, i.e. to load the scaffold with the newly 
released SY MSC, with a simple in theatre centrifugation procedure; however, this may 
increase anaesthetic times, and potentially costs.  
 
For advanced osteoarthritis (OA-grades 3-4), this purpose built device can be used in 
procedures that are currently being researched, as an alternative to total knee 
replacement (TKR). Knee joint distraction (KJD) is currently available within the 
Netherlands and USA (see Figure 38). It involves a technique whereby the joint is 
separated using an external fixation method. This altered mechanics results in 
unloading the joint for a period of time (six weeks) (Wiegant et al, 2013), whilst still 
permitting the patient to fully weight bear through the joint. Separation and reduction of 
joint forces, allows the joint articular surface to regenerate, possibly by allowing 
resident SF MSC to attach to injured sites. The mechanism by which the cartilage 
regenerates has hitherto not been defined. In its infancy of being a viable treatment 
option for knee OA, long-term outcomes are not comprehensively assessed; however, 
in a stimulated study comparing KJD and TKR, cost effectiveness ranks highly with 
KJD over TKR (Van der Woude et al, 2016). If SY MSC were released and augmented 
with other resident MSC (i.e. SF MSC,) during the distraction period, potentially more 
MSC would be able to attach to defected regions, thus accelerating regeneration of the 
articular cartilage (Van Roemund PM, et al. 1999; Intema F, et al 2011; Baboolal T, et 
al. 2014, Baboolal T, et al. 2016 ).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 -­‐116-­‐	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38: Knee joint distraction. The knee is distracted; demonstrate by the arrows 
direction, resulting in joint surfaces unloading (original images adapted from 
Mastbergen S, et al. 2013).  
 
Although the purpose built device has shown encouraging results with regards to MSC 
augmentation, and chondrogenesis, being a newly developed concept, there could be 
potential apprehensions for its use. For example using the device to assertively release 
MSC from the synovium may in fact damage the synovium itself. However, it has been 
documented for some time that the synovium has the capabilities to regenerate in both 
animal models (Bentley et al, 1975; Theoret et al, 1996) and in humans, following an 
arthroscopic synovectomy (Ostergaard et al, 2001). Another suggestion could be that 
in established OA there are already increased numbers of SF MSC (Jones et al, 2008), 
therefore is there any advantage of releasing more cells? This would indicate that 
indeed established OA, which involves damage to many structures (ligaments, 
meniscus, fat pad, synovium etc), would require further interventions, rather than just 
increasing MSC, such as a change in the joint loading mechanics as demonstrated by 
joint distraction (Mastbergen et al, 2013; Van der Woude et al, 2016; Wiegant et al, 
2013) would alter the mechanical environment of the joint, thus allowing for all released 
MSC to adhere and repair sites of damage.	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 Conclusion  6.8
Existing orthopaedic procedures naturally wash away endogenous knee joint MSC.  
Endogenous MSC can be significantly increased in numbers within the knee joint, 
using a purpose built device to release MSC from the synovium, during an arthroscopy 
procedure. Released MSC demonstrate phenotypic characteristics as described in 
previous studies, verifying their identification as MSC. In addition these released cells 
display good potentials into osteogenic, adipogenic and chondrogenic lineages. 
Synovial MSC adhere to relevant biological scaffolds rapidly, and demonstrate 
migration towards them.  
 
The limitations related to this study have been noted; however, further work into these 
areas will determine whether this novel procedure is useful within the clinical setting. 
These findings provide the basis for the testing of novel regenerative strategies for 
orthopaedics, in which low numbers of joint resident MSC can be augmented, to aid in 
the regeneration of damaged articular cartilage and other joint tissues. This thesis work 
represents a bench to operating theatre strategy, for knee joint repair in a one stage 
cost effective procedure, based on knowledge of in vivo MSC.   
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8. List of abbreviations 
 (3D) Three dimensional  
 
(ACI) Autologous Chondrocyte implantation  
 
(AD MSC) Adipose mesenchymal stromal cells 
 
(ALP) Alkaline phosphatase 
 
(ALZ) Alizarin red 
  
(BM) Bone marrow  
 
(BM MSC) Bone marrow mesenchymal stromal cells 
 
(CaCl) Calcium chloride  
 
(CFU-F) Colony forming unit – fibroblast 
 
(C1) Concept device design 1 
 
(C2) Concept device design 2 
 
(C3) Concept device design 3 
 
(C4) Concept device design 4 
 
(C6) Concept device design 6 
 
(C7) Concept device design 7 
 
(C8) Concept device design  8 
 
(DAPI) 4',6-diamidino-2-phenylindole 
 
(DEPC) Diethylpyrocarbonate 
 
(DMEM) Dulbecco's modified eagle's medium  
 
(DMSO) Dimethyl sulfoxide  
 
(dsDNA) Double stranded DNA 
 
(DNA) Deoxyribonucleic acid 
 
(EGF) Epidermal Growth Factor  
 
(FCS) Fetal calf bovine serum 
 
(FG) Fibrin glue 
 
(GAG) Glycosaminoglycan 
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(GF) Growth factors  
 
(H&E) Hematoxylin and eosin stain 
 
(hPL) Human platelet lysate  
 
(IFP MSC) Intrapatellar fat pad mesenchymal stromal cells 
 
(IgG) Immunoglobulin G 
 
(ISCT) International Society for Cellular Therapy 
 
(KJD) Knee joint distraction  
 
(MACI) Matrix-induced autologous chondrocyte implantation  
 
(MF) Microfracture 
 
(MSC) Mesenchymal stromal cells 
 
(n) Number of sample/donors 
 
(NHS) National Health Service UK 
 
(OA) Osteoarthritis 
 
(OATS) Osteochondral autograft transplantation/transfer system  
 
(OCA) Osteochondral allograft transplantation  
 
(OCT) Optimal control temperature  
 
(PAP) Papanicolaou smear brush 
 
(PB MSC) peripheral blood mesenchymal stromal cells 
 
(PBS) Phosphate buffered solution  
 
(PRP) Platelet Rich Plasma  
 
(PPP) Platelet Poor Plasma  
 
(RT) Room temperature 
 
(SF MSC) Synovial fluid mesenchymal stromal cell 
 
(SDF-1β) Human stromal derived factor 1β  
 
(SY MSC) Synovial mesenchymal stromal cells 
 
(TKR) Total knee replacement  
 
(TGF-β3) Transforming growth factor β3  
 
(TGFβ) Transforming Growth Factor beta  
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(UC MSC) Umbilical cord mesenchymal stromal cells 
 
(VAS) Visual analog score  
 
(VEGF) Vascular Endothelial Growth Factor  
 
(WB) Whole blood  
 
  (WOMAC) Western Ontario and McMaster University Osteoarthritis Index  
 
(Yrs) Years  
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Appendix 1  
            
Media, buffers & materials  
Media or buffer Constituents 
Lysis buffer 1 20mM Tris-HCL, pH 8, 20mM NaCL, 20mM EDTA, 1% 
SDS 
Lysis Buffer 2  150mM Nacl, 10mM EDTA, add Proteinase K (600 
µg/mL) (supplemented with Proteinase K)  
Agrose  4% 
Fibrinogen  23.7 mg/mL 
Thrombin  1000 units/mL 
Calcium chloride (CaCl)  5M 
 (H&E) 
 Hematoxylin and eosin staining 
Adipogenic basc media  DMEM, 10% FCS, 0.5mM Isobutylmethyxantine, 60 µM 
Indomethacine. 
Chrondrogenic basic media  DMEM (high Glucose), Ascorbic-2-Phosphate (As2P) 
200mM, Sodium Pyruvate, Proline, BSA, P/S. 
Osteogenic basic media  DMEM, Foetal Calf Serum (FCS) 10%, As2P 100 µM, 
β-Glycerophosphate 10mM 
 
Media & Reagents (manufactured)  
 
Media / Reagents  Product code Company  
Dulbecco's modified eagle's medium 
DMEM(1X) + GlutaMAXTM-I 61965-026 Gibco
®, Invitrogen 
Stromal macs MSC expansion media  130-091-680 Miltenyi Biotec  
Dulbecco's phosphatase buffered 
saline DPBS(1X)  14190-094 Gibco
®, Invitrogen 
Dimethyl sulfoxide (DMSO)  M81802 Sigma  
Trypsin/EDTA solution  15400-054 Invitrogen  
Penicillin/Streptomycin solution  14140 Gibco®, Invitrogen  
Boric acid B0252 Sigma 
Trypan blue  T8154 Sigma  
Methylene blue stain  66720 Fluka  
Fetal calf serum (FCS)  A3059-500g Sigma 
Formaldehyde  BP531-500 Fischer Scientific  
Quanti-iTTM dsDNA Assay Kit 1458609 Invitrogen 
Sulfated glycosaminoglycan assay kit B1000 Blyscan™ 
Calcium assay kit 17667 Senitial Diagnostics 
G|2 Doublestain system Rabbit/Mouse K5361 EnVisionTM  
Equipment 
Equipment 
 
 
 
Product code Company  
Inverted microscope  DMIL090-135.001 Leica MicrosyStromals 
Inverted microscope CKX41 Olympus 
Digital camera  C-7070  Olympus 
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Plastic devises 
 
 
Mechanical freezer -80°C ULTF 80 Dairel 
Liquid nitrogen NA NA 
Centrifuge PK 130 R ACL 
Centrifuge 5810 R Eppendorf 
Centrifuge Z 206 A Hermle 
Sterile surgical dissection kit  NA NA 
PAP brush NA CERVIBRUSH TM + CE 
Devices C1, C2, C3, C4, C6, C7 NA NA 
Incubated at 37 oC, 5% CO2  50100783 Sanyo 
Haemocytometer BS.748 Hawksley 
8 mm Diameter Core Extruder NA Arthrex OATSTM 
3.2% sodium Citrate anticoagulation 
blood collection tube A1403IES Vacuette
®  
37 oC water bath NA Grant 
Plastic-ware  Product code Company  
Pasteur pipettes sterile 1mL 1170915 Gilson 
Pipette tips (1000 µL)  F167104 Gilson 
Pipette tips (200 µL)  F167103 Gilson  
Pipette tips (10 µL)  F167101 Gilson  
Stripette (25 mL)  4251 Corning  
Stripette (10 mL)  4101 Corning  
Stripette (5 mL)  4051 Corning  
96 well plate (round bottom)  3799 Corning  
6 well plates  3516 Corning  
48 well plate 3548 Corning 
15 mL Falcon tubes 430790 Corning  
50 mL Falcon tubes 430828 Corning 
Flask (25 cm2)  430639 Corning  
Flask (75 cm2)  430641 Corning  
Flask (150cm2) 430825 Corning 
Petri-dish (10cm diameter)  430167 Corning  
Cryovials (2 mL)  72.380 Sarstedt 
Cryovials (1.2 mL) 72.377.005 Sarstedt 
Cryo boxes 93.872.625 and 93.876.281 Sarstedt 
Syringe (10 mL)  302188 BD  
Centrifuge tubes (15 mL)  430790 Corning  
Centrifuge tubes (50 mL)  430828 Corning  
 
 brush verses purpose built device. 	  
(A) Calder Brush (purpose built device) (B) PAP Brush 
A 
B 
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Condrogenic differentiation assay SOP  
 
Equipment needed 
 
Laminar flow cabinet 
CO2 incubator at 37oC 
Waterbath 
Small Eppendorfs with screw caps 
Pastettes 
Sterile pipettes 
Gloves 
Syringe and needle 
 
Reagents required 
 
Chondro medium:- 
 
DMEM (Gibco/Life Tech 61965-059) 500mL 
As2P (Sigma A8960, 5g) 200mM stock 0.5mL 
Sodium Pyruvate (Sigma S8636) 100x concentrated stock 5mL 
Proline (Sigma P5607) 20mg 
BSA (Sigma a-7906) 500mg 
Penicillin/Streptomycin ((Gibco/Life Tech 15140-122) 5mL 
PBS (Gibco LifeTech 14190-169) 
Papain (Sigma P4762) 
 
Supplements added to Media  
 
Dexamethasone (Sigma D1756, 25mg) 1µL 
TGFβ3 (R&D System, 243-B3-002, 2µg) 50µg 
ITS+ (Sigma 12521) 1:100 50µL 
 
PBS (GIBCO LifeTech 14190-169) 
 
Papain 
 
Na2 HPO4 
NaH2PO4 
Acetyl cysteine 
EDTA 
 
sGAG assay eg Wieslab AB GAG 201                                                                                                                                                                                                                                                                                                                                                                                                            
 
Method    
 
Trypsinise cells, resuspend in 0.5 mL DMEM/2% FCS and count. 
Each chondrogenic assay requires 0.25x106 cells. Try to replicate at least twice (total 
require 0.5x106 cells) . 
Place cells in Eppendorf tubes and make up the volume to 0.5mL with DMEM/2 % FCS 
and spin at 2000rpm for 5 minutes. 
Avoiding the pellet, gently remove the medium with a tip of a pipette or pastette, break 
the pellet by tapping and re-suspend in 0.5mL complete chondrogenic media. 
Centrifuged for 2000rpm for 5miuntes, observe the pellet, loosen the tops and incubate 
in CO2 incubator at 37ºC. 
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Half media changes three times per week (Mon, Weds and Fri) by removing 0.25mL of 
medium and replacing with 0.25mL fresh medium. 
After 3 weeks, stop the assay by carefully removing the medium with a syringe and 
needle.  
Wash twice with PBS. 
Add 100µl papain, replace lid tightly and incubate at 65ºC overnight in the waterbath. 
Mix contents well, spin at 5000rpm for 5 minutes and freeze at –20ºC (do not remove 
supernatant, freeze whole tube). 
Perform GAG assay according to manufacturers instructions. 
 
 
 
PREPARATION OF STOCK SOLUTIONS 
 
BASIC CHONDRO MEDIUM 
 DMEM (Gibco/Life Tech 61965-059)  500mL 
As2P 200mM stock    0.5mL   
Sodium pyruvate 100x stock   5mL   
Proline      20mg   
BSA      500mg   
P/S      5mL   
 
Weigh out BSA and proline, dissolve in a minium of DMEM, filter into a sterile bottle. 
Aseptically add other reagents, mix well and aliquot in 5mL volumes, store at –20ºC. 
 
 
ASCORBIC-2-PHOSPHATE As2P (Sigma A8960, 5g) 
Make 200mM stock by dissolving 2.895g in 50mL water. Aliquot at 60µL (for Osteo 
assay) and 0.5mL and freeze at –20ºC. Add 0.5mL to 500mL DMEM. 
 
SODIUM PYRUVATE (SIGMA S8636) 
100Mm ie 100x concentrated. Stored at 4ºC, use at 5mL per 500mL DMEM. 
 
PROLINE (Sigma P5607) 
Stored at room temperature. 
 
BSA (SIGMA A-7906) 
Stored at 4ºC. 
 
Penicillin/Streptomycin (Gibco/Life Tech 15140-122) 
Aliquoted in 5mL vols and stored at –20ºC. 
 
Dexamethasone (Sigma D1756, 25mg) 
As per Osteo assay:- Make 50mM stock solution by adding 1280µL 100% ethanol to 
25mg. Aliquot in10µL volumes , freeze at –20ºC. Prior to use 10µL is added to 1mL 
medium to give 500µM stock and refrozen in 10µl aliquots. Then make a 1:5000 
dilution to give a final concentration of 10nM. 
 
TGFβ3 (R & D Systems, 243-B3-002 2µg) 
a)Make a diluent of 4mM Hcl containing 1mg/mL BSA :- 
1M HCl – add 86.2% HCl to 1L water or 2.15mL to 25mL water. 
Dilute by 1:250 to give a 4mM concentration ie 100µL of 1m in 25mL water. 
b)Add 25mg BSA to 25mL 4mM HCl to produce desired diluent. 
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c)Dissolve 2µg TGFβ3 I 2mL of diluent to give 1µg /mL TGFβ3 stock solution. 
Aliquot in 20µL volumes and store at –20ºC.   
 
Supplements to be added immediately before use to produce complete Chondro 
medium 
     Vol to add to 5mL base medium 
ITS+ (Sigma 12521) 1:100    50µL 
TGFβ3 1:100      50µg 
Dexamethasone 500µM    1µL 
 
PAPAIN (SIGMA P4762) 
Prepare buffer:- 
50mM sodium phosphate pH 6.5  :-mix 3mL of 1M Na2HPO4 (1.42g/10 mL) with 7mL of 
NaH2PO4 (1.56g/10mL) and top up to 200mL with water. 
2mM Acetyl cysteine (Sigma A7250) :- prepare 100mM solution (1.63g/100mL water) 
and dilute 50 fold (use 4mL in 200mL of phosphate buffer). 
2mM EDTA 
Mix all reagents together, check pH = 6.5.  
Dissolve 100mg papain in 100mL of the above buffer, filter through a 0.2µ filter, aliquot 
in 1mL volumes and freeze at –20ºC. 
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Osteogenic differentiation assay SOP  
Equipment Needed 
 
Laminar flow cabinet 
CO2 incubator 
Haemacytometer 
Pastettes 
Sterile pipettes 
Gloves 
Sterile 12 or 6 well plates 
1 mL syringe and 19/23G needle 
1.5mL Eppendorf 
Cell scrapers 
 
Reagents needed 
Osteogenic medium DMEM (GIBCO/Life Tech 14190-169)  
   Foetal calf serum (FCS) 10% 
   Ascorbic-2-phosphate (As2P) 100µM 
   β glycerophosphate 10mM 
   Dexamethasone 100nM 
DMEM / 2%FCS 
Trypsin 
0.5N HCl 
PBS (NB must be Calcium-free) 
Commercial calcium assay kit eg Sigma 587-A 
 
 
PREPARATION OF STOCK SOLUTIONS 
 
 
DEXAMETHASONE (SIGMA D1756 25mg) 
(1M = 392.5mg/mL or 25mg/0.064mL) 
25mg in 640µL = 100mM, or 25mg in 1280µL = 50mM 
Dissolve 25mg in1280µL of 100% ethanol to give 50mM stock solution. Aliquot this 
solution in 10µL volumes in sterile vials and store at –20oC. 
10µL of 50mM is added to 1mL of medium to give a 500µM solution, which can be 
refrozen in 10µL aliquots. This is then added to medium just before use at a 1:5000 
dilution ie 20µL to 100mL of medium. 
 
ASCORBIC-2-PHOSPHATE (SIGMA A8960, 5g) 
(1M = 257 mg/mL or 2.57g/10mL) 
2.57g/100mL = 100mM. 
Dissolve 2.57g in 50mL of water to give 200mM stock solution. This can be aliquoted in 
1.0mL and 60µL volumes (and 0.5mL for chondro assay) and stored at –20oC. Use at a 
1:2000 dilution ie 50µL of stock to 100mL of medium. 
 
BETA-2-GLYCEROPHOSPHATE (SIGMA G6251, 10g) 
(1M 216g/L or 10g/46mL) 
Dissolve 10g in 23mL of water to give 2M stock. This can be frozen at –20oC in sterile 
vials. Use at a 1:200 dilution to give a10mM dilution eg  0.5mL in100mL of media. 
 
 
Medium containing both glycerophosphate and ascorbic-2-phosphate can be prepared 
and frozen.  
 -­‐140-­‐	  
 
TRYPSIN (GIBCO/LIFE TECH 34500-027) 
Aliquoted in 2mL universals and stored at –20ºC. Add 18mL PBS just before use. 
 
FCS (GIBCO 10106-169) 
Aliquoted in 10mL universals and stored at –20ºC. 
 
0.5N HCl 
26.5mL 37% HCl + 473.5mL dd water. 
 
 
Method 
 
Steps 1 – 5 must be carried out aseptically in the laminar flow cabinet, wearing 
gloves. 
 
Trypsinise cells, make up to 0.5mL in DMEM / 2% FCS, keep on ice while counting. 
Calculate the volumes required. 
6 well plate needs 0.03 million cells/well 
12 well plate needs 0.01 million cells/well 
3 replicates are essential 
Add required medium to the wells 
6 well plate requires 4 mL/well 
12 well plate requires 2mL/well 
Add the cells to the medium, swirl gently and incubate at 37oC in the CO2 incubator. 
The cells need feeding twice per week eg Monday and Friday. Remove half the volume 
of medium and replace with fresh medium. 
The assay lasts for 3 weeks, for Calcium and Alizarin, and 2 weeks for Alkaline 
Phosphate assay.  
 
Calcium Assay 
 
To stop the assay, remove medium and wash twice with PBS. 
Add 1mL for 6 wells, 0.3mL for 12 wells of 0.5N HCl, leave for 5 minutes at room 
temperature. 
Using a cell scraper (large wells) or a pastette  (small wells) gently scrape the cells off 
the surface 
Aspirate with a 1mL syringe and 19G/23G needle  
Transfer to 1.5mL Eppendorf (conical), ensure lids are tight. 
Mix for 4hours at 4oC using rotator. 
Transfer to -20oC freezer. 
When ready to perform calcium assay:- 
Thaw cells at room temperature 
Centrifuge at 8000g for 5 minutes (8000rpm in small centrifuge) 
Transfer to fresh Eppendorf 
Perform Ca assay according to the manufacturers instructions Plese see (To Measure 
Ca++) 
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Suggested lay out.  
(Colour is stable for up to 1 hour therefore no absolute need to spread the standards 
across the plate). 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 100 mg/mL Sample 1       
B 50 mg/mL Sample 2       
C 25 mg/mL Sample 3       
D 12.5 mg/mL etc       
E 6.25 mg/mL          
F 3.125 mg/mL          
G 1.5625 mg/mL          
H BLANK          
 
Centrifuge thawed samples for 5 min at 8000rpm. Use the supernatant, by either 
plating 4µL directly into clear flat bottomed plate (not TC plate), in triplicate, or transfer 
to round bottomed plate to enable transfer by multichannel pipette. 
 
Prepare standard curve from 1000mg/L stock. A1 – 3 is neat. Prepare the remainder 
by serial dilution, ensuring excess is removed from G. Dilutions can be made either in 
calcium free water, or in 0.5N HCl. Again, transfer 4 µL to each of the relevant wells. 
 
Sentinel diagnostic (ref: 17667, Italy), 
 
NOTE: Standard curve MUST be done on EVERY PLATE. 
Prepare Calcium Liquid according to ratio below, enough for 200 µl per well.  
(Do not use weigh boats, they appear to contain calcium). 
  
Reagent 1 : Reagent 2 
 5mL : 2mL 
 
Pipette Calcium reagent using a multichannel pipette. 
 
The colour change is immediate, measure the absorbance at 570 nm, ideally within 30 
minutes. 
 
NOTE: If reading is outside that of the standard curve, the sample should be diluted 
(using the same diluent as above) and tested again on a fresh plate, including a 
standard curve. 
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Alkaline Phosphatase SOP 
 
 
Fast blue RR Salt Sigma FBS-25 -20° 
Naphthol AS-MX phosphate alkaline solution Sigma 85-5 +4° 
Mayers Haematoxylin Sigma MHS-1 
Citrate concentrated solution Sigma 85-4C 
Ca++ free PBS 
 
Adapted for 3cm dishes. 
 
Prepare citrate working solution – 2mL citrate concentrate to 98mL deionised water 
(scale down as necessary). 
 
Prepare fixative, 2 volumes citrate working solution to 3 volumes acetone. Discard 
after use 
 
Prepare Fast Blue Solution - Measure 48mL distilled water, bring to RT, dissolve 1 
capsule Fast blue RR salt into the distilled water, wrap in foil to protect from light. (may 
need stirrer or warm in 37 degree waterbath). Once dissolved add 2mL Naphthol AS-
MX phosphate alkaline solution to Fast Blue solution. 
 
GENTLY aspirate media from dishes; GENTLY wash with PBS (x2). 
Remove PBS and then add 2mL fixative for 30 seconds, wash in distilled water x2 - do 
not allow to dry. 
Add Fast Blue dye mixture and incubate at RT for 30 minutes in the dark 
Wash twice with deionised water 
Add 2mL Mayer’s haematoxylin for 10 minutes 
Wash in deionised water (x2 or x3) 
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Adipogenic differentiation assay SOP 
 
SOP Number: Alam 
 
Equipment needed 
 
Laminar flow cabinet 
CO2 incubator at 37oC 
Hemacytometer 
Inverted microscope 
12 or 24 well plates 
Fine tweezers 
Glass coverslips, 16mm for 12 well plates, 13mm for 24 well plates 
Leica microscope 
Microscope slides 
Sterile pipettes 
Pastettes 
Gloves 
0.8µ pore filter 
Reagents needed 
 
Adipo medium :-   
DMEM  
10% foetal calf serum (FCS) (GIBCO 10106-169)  
10% horse serum (STEM CELL TECHNOLOGIES 06750) 
0.5 mM isobutylmethylxantine (SIGMA I5879) 
60 µM indomethacin (ICN) 
0.5 mM hydrocortisone (SIGMA H2270) 
DMEM / 2% FCS 
Trypsin 
70% ethanol 
Oil red   
PBS (GIBCO/Life Tech 14190-169) 
10% formalin 
Harris’s Haematoxylin, freshly filtered 
Aquamountant  (BDH 362262H) 
 
Method 
 
Steps 1 – 7 should be carried out aseptically in the laminar flow cabinet wearing 
gloves. 
 
1. Trypsinise cells, re-suspend in 0.5mL DMEM / 2% FCS, leave on ice while counting.  
2. Calculate the volume of cells required per well.  
For a 12 well plate 0.1 million cells per well are needed. 
For a 24 well plate 0.05 million cells per well are needed. 
Ideally 3 replicates are required, but 1 is adequate if necessary. 
3. Sterilise the coverslips in ethanol using the tweezers and place in the wells. 
4. Wash the coverslips twice in PBS to remove the ethanol. 
5. Add the medium to the wells. 
1mL / well for 24 well plate, 2mL / well for 12 well plate. 
6. Add cells to wells, swirl gently and incubate in CO2 incubator at 37oC. 
7. Feed cells twice a week by aseptically removing half the medium and replacing it 
with fresh medium on eg Monday and Friday. Continue for 3 weeks. 
8. To stop the assay, remove the medium using a pastette and rinse twice with  
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PBS. 
9. Fix with 10% formalin for 10 minutes. 
10. Place Oil Red at 37°C for minimum of 30 minutes. Dilute the stock Oil Red in 
distilled water, 3 parts Oil Red to 2 parts water, then filter through a 0.8µ pore filter 
followed by 0.2µ filter to remove particles. 
11. Remove formalin, wash twice with PBS, add filtered Oil Red 1mL / well for 10 
minutes. 
12. Remove Oil Red, wash twice with PBS. 
13. Add filtered haematoxylin for 45 seconds then rinse in cold tap water. 
14. Place 1 drop of mountant on a slide. 
15. Remove coverslip with tweezers and place cell side down on the mountant. 
16. Examine under the microscope. 
  
 
 
PREPARATION OF STOCK SOLUTIONS 
 
ISOBUTYLMETHYLXANTINE (SIGMA I5879) 
(For a 1M solution use 222mg / mL) 
Weigh out 200mg and dissolve in 1.8mL DMSO to make a 0.5M stock solution. Filter 
through a 0.2µ pore size filter. This stock solution can be aliquoted in 100µL volumes 
and frozen at –20oC. 100µL is added to 100mL of medium (ie 1:1000) to give a final 
concentration of  0.5mM . 
 
INDOMETHACINE (ICN)  
(For 1M solution use 358 mg/mL or 100mg in 280µL) 
Make up a 0.6M stock solution by dissolving100µg in 467µL of DMSO. Filter sterilise 
and aliquot in 10µL volumes and freeze at –20oC. 10µl is added to100mL of medium 
(ie 1:1000) for use. 
  
HYDROCORTISONE (SIGMA H2270) 
 Make up 10-4M solution eg 4.845mg in100mL of PBS. Filter sterilise and freeze at –
20oC in 100µL volumes. Add to basic adipo medium immediately before use. 50µL per 
10mL 
 
HORSE SERUM (STEM CELL TECHNOLOGIES 06750) 
Stored at –20oC in10mL aliquots.  
 
5.   FOETAL CALF SERUM (GIBCO 10106-169) 
Stored at –20oC in 10mL aliquots. 
 
OIL RED (SIGMA O0625) 
0.5% in isopropanol ie 50mg in10mL 
 
TRYPSIN (GIBCO BRL 34500-027) 
Aliquoted in 2mL volumes and stored at –20oC. For use add 18mL PBS.  Use 
approximately 5mL per small flask. 
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Measurement Of Adipogenrc Differentiation by N110 Red on the plate reader  	  	  
1) Design 48 well late to required layout below, do not use the outer 
rows/coloums of wells. In triplicate wells seed 40,000 MSC per test sample for 
both adipo and NH media.  
 
2. Feed as per standard NH and adipo induction for 21 days. .  
 
3. Make up Nile red stock solution of 10mg/mL in methanol aliquot and freeze at 
-20OC.   
 
4. Remove media from wells.  
 
5. Wash wells twice carefully in PBS.   
 
6. Add 200ul 4% formalin in PBS and leave for 30min.  
 
7 Make up 0.2% saponin in PBS (measure out in hood, and only remove from 
hood if covered, saponin powder is toxic). This needs to be fresh each time. ..  
 
8. To Saponin solution add nile red and DAPI to a working concentration of 
(100uL of DAPI, and 100uL of NILE red stock), 1ug/ml, protect from light. 
 
9. Remove formalin from wells.  
 
10. Wash twice with PBS.  
 
11. Add 200ul PBS to each well, be precise.  
 
12. Read plate on Berthold plate reader (level 9) using DAPI and Nile red-FITC. 
The points should be set to 5 and area 2.38 for each reading. Check the plate 
layout before reading. This will give a background reading  
 
13. Remove PBS from wells  
14. Add 200ul 0.2% saponin/lug/ml nile red/lug/ml DAPI solution to each well.  
 
15. Incubate for 15min in foil at room temperature.  
 
16. Remove liquid from wells, and wash 3 times with PBS   
 
17. Add 200ul PBS (careful precise pipetting is required), wrap plates in foil.   
 
18. Read plate on Berthold plate reader (level 9) using DAPI and Nile red-FITC 
The points should be set to 5 and area 2.38 for each reading. Check the plate 
layout before reading. The filter slide is A (DAPI 355/460 and Nile Red  
485/535)  
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19. Keep in fridge if fluorescent pictures are required. –  
 
20. For analysis subtract the background reading and then do a ratio of Nile 
Red to DAPI  
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EnVisionTM G|2 Doublestain System, Rabbit/Mouse (DAB+/Permanent Red) Code 
K5361 
 
Protocol: 
A. Reagent preparation  
A.1 DAB+ Working Solution DAB+ Working Solution is prepared by thoroughly mixing 1 
mL of DAB+ Substrate Buffer (Vial 3) with 1 drop (25-30 µL) of DAB+ Chromogen (Vial 
4). Each 1 mL aliquot is sufficient for 10 tissue sections. Prepare only the volume 
required for the number of slides that shall be stained. Prepared DAB+ Working 
Solution is stable for approximately 5 days when stored at 2-8 °C. This solution should 
be mixed thoroughly prior to use. Any precipitate developing within 5 days in the 
solution does not affect staining quality. DAB+ Working Solution should be prepared in 
an Autostainer Reagent Vial when used on the Dako Autostainer instrument.  
 
A.2 Permanent Red Working Solution Permanent Red Working Solution is prepared by 
thoroughly mixing 100 parts of Permanent Red Substrate Buffer (Vial 8) with 1 part of 
Permanent Red Chromogen (Vial 9), e.g. mix 1 mL Permanent Red Substrate Buffer 
(Vial 8) with 10 µL Permanent Red Chromogen (Vial 9). Prepare only the volume 
required for the number of slides that shall be stained. Use the solution within 30 
minutes. Permanent Red Working Solution should be prepared in an Autostainer 
Reagent Vial when used on the Dako Autostainer instrument.  
 
A.3 Guideline for optimal dilution of primary antibodies EnVision™ G|2 Doublestain 
System is compatible with suitably diluted Dako concentrated primary antibodies. 
Optimal dilution should be determined by the user.  
 
B. Staining procedure for manual use  
B.1 Procedural notes The following pre-treatment steps should be carried out before 
using EnVision™ G|2 Doublestain System on formalin-fixed, paraffin-embedded tissue 
sections. The specimen should be deparaffinized and rehydrated. Some specimens 
should be subjected to epitope demasking by heat-induced epitope retrieval or enzyme 
digestion. Please refer to the package insert of the individual primary antibody for 
specific information on specimen preparation. Following demasking, the specimen 
should be rinsed gently with wash buffer solution from a wash bottle (do not focus 
directly on tissue) and placed in a fresh wash buffer bath for 5 minutes.  
 
All reagents should be equilibrated to room temperature (20-25 °C) prior to 
immunostaining. Likewise, all incubations should be performed at room temperature.  
 
Do not allow specimens to dry out during the staining procedure. Dried specimens may 
display increased non-specific staining.  
 
B.2 Staining protocol  
Step 1: Vial 1, Dual Endogenous Enzyme Block Tap off excess wash buffer and 
carefully wipe around the specimen to remove any remaining liquid and to keep the 
reagent within the prescribed area. Apply 200 µL Dual Endogenous Enzyme Block to 
cover specimen. Incubate for 5 (± 1) minutes. solution from a wash bottle (do not focus 
directly on tissue) and place in a fresh wash buffer bath for 5 minutes.  
 
Step 2: Primary antibody No. 1 or negative control reagent No. 1 Tap off excess wash 
buffer and wipe slides as before. Apply 200 µL mouse or rabbit primary antibody or 
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negative control reagent (see section A.3) to cover specimen. Incubate for 10 (± 1) 
minutes. Rinse specimen as described in Step 1.  
 
Step 3: Vial 2, Polymer/HRP Tap off excess wash buffer and wipe slides as before. 
Apply 200 µL Polymer/HRP to cover specimen. Incubate for 10 (± 1) minutes. Rinse 
specimen as described in Step 1, twice.  
 
Step 4: DAB+ Working Solution Prepare DAB+ Working Solution as described in 
section A.1. Tap off excess wash buffer and wipe slides as before. Apply 200 µL DAB+ 
Working Solution to cover specimen. Incubate for 5-15 minutes. Optimal incubation 
time may vary and should be determined by each individual laboratory. Rinse 
specimen gently with distilled or deionised water from a wash bottle (do not focus 
directly on tissue). Collect DAB+ Working Solution waste in a hazardous materials 
container for proper disposal. If the staining procedure must be interrupted, slides may 
be kept in a wash buffer bath following incubation of DAB+ Working Solution for up to 
one hour at room temperature (20-25 °C) without affecting staining result.  
 
Step 5: Vial 5, Doublestain Block Tap off excess wash buffer and wipe slides as before. 
Apply 200 µL Doublestain Block to cover specimen. Incubate for 3 (± 1) minutes. Rinse 
specimen as described in Step 1.  
 
Step 6: Primary antibody No. 2 or negative control reagent No. 2 Tap off excess wash 
buffer and wipe slides as before. Apply 200 µL optimally diluted mouse or rabbit 
primary antibody or negative control reagent (see section A.3) to cover specimen. 
Incubate for 10 (± 1) minutes. Rinse specimen as described in Step 1.  
 
Step 7: Vial 6, Rabbit/Mouse (LINK) Tap off excess wash buffer and wipe slides as 
before. Apply 200 µL Rabbit/Mouse (LINK) to cover the specimen. Incubate for 10 (± 1) 
minutes. Rinse specimen as described in Step 1, twice.  
 
Step 8: Vial 7, Polymer/AP Tap off excess wash buffer and wipe slides as before. 
Apply 200 µL Polymer/AP to cover the specimen. Incubate for 10 (± 1) minutes. Rinse 
specimen as described in Step 1, twice.  
 
Step 9: Permanent Red Working Solution Prepare Permanent Red Working Solution as 
described in section A.2. Prepared Permanent Red Working Solution should be used 
within 30 minutes. Tap off excess buffer and wipe slides as before. Apply 200 µL 
Permanent Red Working Solution to cover the specimen. Incubate for 5-20 minutes. 
Optimal incubation time may vary and should be determined by each individual 
laboratory. Rinse slides gently with distilled or deionised water from a wash bottle (do 
not focus directly on specimen). Collect chromogen-containing waste in a hazardous 
materials container for proper disposal. Place rinsed slides in a fresh distilled or 
deionised water bath for 5 minutes.  
 
Step 10: Counterstain (instructions are for hematoxylin) Immerse slides in a bath of 
hematoxylin. Length of incubation time depends on the strength of hematoxylin used. 
Follow hematoxylin counterstaining with a thorough rinse in distilled or deionised water. 
Optional: Immerse tissue slides into a bath of 37 mmol/L ammonia water and rinse 
gently in distilled or deionised water for 2-5 minutes. Ammonia water (37 mmol/L) is 
prepared by mixing 2.5 mL of 15 mol/L (concentrated) ammonia hydroxide with 1 litre 
of distilled or deionised water. Unused 37 mmol/L ammonia water may be stored at 
room temperature (20-25 °C) in a tightly capped bottle for up to 12 months.  
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Step 11: Mounting For aqueous mounting, mounting media such as Dako Glycergel™ 
Mounting Medium, code C0563 or Faramount Aqueous Mounting Medium code S3025 
is recommended. (114055-002) 
 
Vial 1  
3 x 11 mL Dual Endogenous Enzyme Block  
Ready-to-use.  
Endogenous enzyme block solution, containing 0.5% hydrogen peroxide, detergents, 
enzyme inhibitors, and preservative, pH 2.  
 
Vial 2  
3 x 11 mL Polymer/HRP  
Ready-to-use. 
Dextran polymer conjugated with horseradish peroxidase and affinityisolated 
immunoglobulins. Supplied in Tris/HCl buffer containing stabilizing protein and 
preservative.  
 
Vial 3  
3 x 11 mL DAB+ Substrate Buffer  
Substrate buffer solution, pH 7.5, containing <0.1% hydrogen peroxide, stabilizers, 
enhancers, and an antimicrobial agent.  
 
Vial 4  
1 x 1.5 mL DAB+ Chromogen  
5% 3,3’-diaminobenzidine tetrahydrochloride chromogen solution.  
 
Vial 5  
3 x 11 mL Doublestain Block  
Ready-to-use.  
Blocking solution.  
 
Vial 6  
3 x 11 mL Rabbit/Mouse (LINK)  
Ready-to-use.  
Dextran polymer coupled with secondary antibodies against mouse and rabbit 
immunoglobulins. In buffered solution containing stabilizing protein and preservative.  
 
Vial 7  
3 x 11 mL Polymer/AP 
Ready to use 
Dextran polymer conjugated with alkaline phosphatase and affinity-isloted 
immunoglobulins. Supplied in Tris/HCl buffer containing stabilizing protein and a 
preservative.  
 
 
Vial 8  
3 x 11 mL Permanent Red  
Substrate Buffer Substrate buffer solution.  
 
Vial 9  
1 x 300 µL Permanent Red Chromogen  
Permanent Red Chromogen solution. 
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Primary Antibodies used: 
 
DAKO CD45 (monoclonal mouse) Leucocytes Common Antigen-Human  
Ref: Mo701 (1:50) 
 
RabMAb® Anti-CD73 EPR6114 (ab133582) (1:100) 
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Appendix 2 
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PATIENT	  INFORMATION	  SHEET	  	  
Re:	  	  
	  
Collection	  of	  joint	  mesenchymal	  stem	  cells	  (MSC)	  
	  
PI:	  Professor	  D	  McGonagle	  	  
	  
Collection	  of	  Knee	  Tissues	  after	  Total	  Knee	  Replacement	  	  You	  are	  being	   invited	   to	   take	  part	   in	  a	  RESEARCH	  study.	  Before	  you	  decide,	   it	   is	  important	  for	  you	  to	  understand	  why	  the	  research	  is	  being	  done	  and	  what	  it	  will	  involve.	   Please	   take	   the	   time	   to	   read	   the	   following	   information	   carefully	   and	  discuss	  it	  with	  friends	  and	  relatives	  if	  you	  wish.	  Please	  ask	  us	  if	  there	  is	  anything	  that	   is	   not	   clear,	   or	   if	   you	   would	   like	   more	   information.	   Take	   time	   to	   decide	  whether	  or	  not	  you	  wish	  to	  take	  part.	  	  	  Thank	  you	  for	  reading	  this.	  	  
1.	  What	  is	  the	  purpose	  of	  the	  study?	  Special	   cells	   in	   the	   body	   termed	   Mesenchymal	   Stem	   Cells	   (MSC)	   can	   make	  	  cartilage,	  bone,	  muscle,	  tendon	  and	  ligament.	  MSC	  have	  been	  found	  in	  many	  tissues	  to	  date	  but	  just	  how	  they	  work	  is	  still	  not	  understood.	  There	  is	  interest	  in	  the	  use	  of	  MSC	  as	  a	  way	  of	  repairing	  damaged	  joints	  and	  bones.	  Our	  research	  is	  aimed	  at	  understanding	  how	  these	  cells	  work	  in	  health	  and	  in	  disease.	  	  	  	  
2.	  Why	  have	  I	  been	  chosen?	  Osteoarthritis	   has	   been	   estimated	   to	   affect	   approximately	   20	   per	   cent	   of	  population	   over	   60	   and	   so	   are	   of	   great	   importance.	   Osteoarthritis	   is	   a	   painful	  illness	   causing	   inflammation	   (or	   soreness)	   in	   the	   joints.	   The	   main	   cause	   is	   the	  alternations	  in	  joint	  movements,	  the	  eventual	  loss	  of	  the	  articular	  cartilage	  and	  the	  excessive	   bone	   formation	   which	   cause	   narrowing	   in	   the	   joint	   space	   and	  remodelling	  of	  bone.	  	  This	  may	  eventually	  require	  joint	  replacement.	  	  
As	  part	  of	   you	  normal	  arthroscopic,	   open	  knee	   surgery	  or	   joint	  replacement	  
procedure	   any	   removed	   joint	   tissue	   or	   joint	   fluid	   is	   normally	  discarded.	   	  We	  would	  like	  to	  use	  these	  diseased	  tissue	  and	  fluid	  to	  study	  the	  function	  of	  MSC.	  We	  will	  grow	  these	  cells	  in	  the	  laboratory	  for	  a	  short	  time	  and	  then	  study	  their	  ability	  to	  make	  cartilage	  and	  bone.	  	  	  	  In	   addition	   suitable	   patient	  will	   be	   chosen	   to	   have	   their	   stem	   cells	   retrieved	   by	  sampling	  of	  the	  joint	   lining	  during	  arthroscopic	  procedures	  using	  a	  cytology/PAP	  brush,	   This	   will	   be	   undertaken	   with	   sterile,	   single	   use	   instrumentation	   already	  approved	   for	   use	   in	   man.	   The	   collection	   of	   cells	   in	   this	   way	   will	   be	   minimally	  invasive,	  would	  only	  add	  a	  few	  minutes	  on	  to	  the	  operative	  time.	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3.	  Do	  I	  have	  to	  take	  part?	  It	  is	  up	  to	  you	  to	  decide	  whether	  or	  not	  to	  take	  part.	  If	  you	  decide	  to	  take	  part,	  you	  will	  be	  given	  this	  information	  sheet	  to	  keep	  and	  be	  asked	  to	  sign	  a	  consent	  form.	  If	  you	   decide	   to	   take	   part,	   you	   are	   still	   free	   to	  withdraw	   at	   any	   time	   and	  without	  giving	  a	  reason.	  This	  will	  not	  affect	  the	  standard	  of	  care	  that	  you	  receive.	  	  
4.	  What	  will	  happen	  to	  me	  if	  I	  take	  part?	  If	  you	  decide	  to	  take	  part	  you	  will	  be	  asked	  to	  sign	  an	  informed	  consent	  form,	  and	  you	  will	  be	  given	  a	  copy	  of	  the	  information	  sheet	  and	  the	  signed	  consent	  form	  to	  keep.	   You	  will	   be	   asked	   to	  donate	   your	   joint	   tissues	  normally	   thrown	  after	   your	  operation.	  	  	  Some	  suitable	  patient	  will	  be	  chosen	  to	  have	  their	  stem	  cells	  retrieved	  by	  sampling	  of	  the	  joint	  lining	  during	  arthroscopic	  procedures	  using	  a	  cytology/PAP	  brush,	  This	  will	   be	  undertaken	  with	   sterile,	   single	  use	   instrumentation	  already	  approved	   for	  use	   in	  man.	  The	   collection	  of	   cells	   in	   this	  way	  will	   be	  minimally	   invasive,	  would	  only	  add	  a	  few	  minutes	  on	  to	  the	  operative	  time.	  	  
5.	  What	  do	  I	  have	  to	  do?	  There	  are	  no	  other	  requirements/tests	  needed	  beyond	  the	  surgical	  procedure.	  	  It	   is	  very	  important,	  when	  giving	  your	  medical	  history	  to	  the	  doctor,	  that	  you	  tell	  him/her	  whether	  or	  not	  you	  are	  regularly	  taking	  any	  medicine.	  	  	  
6.	  What	  are	  the	  side	  effects	  of	  taking	  part?	  For	  patient	   that	  are	  not	  undergoing	  brushing	  of	   the	   joint	   lining	  there	  are	  no	  side	  effects	  as	  knee	  tissues	  are	  normally	   thrown	  after	   the	  operation.	  The	  collection	  of	  	  MSC’s	  with	  the	  	  cytology/PAP	  brush	  is	  not	  harmful	  to	  the	  patient,	  and	  uses	  a	  brush	  that	  already	  is	  commonly	  used	  within	  humans.	  	  	  
7.	  What	  are	  the	  possible	  benefits	  of	  taking	  part?	  You	  will	  not	  benefit	  directly	  from	  taking	  part	  in	  this	  research	  and	  all	  other	  aspects	  of	  your	  care	  will	  be	  the	  same	  as	  if	  you	  did	  not	  take	  part.	  	  
8.	  What	  if	  something	  goes	  wrong?	  If	   you	   are	   harmed	   by	   taking	   part	   in	   this	   research,	   there	   are	   no	   special	  compensation	  arrangements.	  If	  you	  are	  harmed	  due	  to	  someone’s	  negligence,	  then	  you	  may	  have	  grounds	  for	  a	  legal	  action	  but	  you	  may	  have	  to	  pay	  for	  it.	  Regardless	  of	   this,	   if	   you	   wish	   to	   complain	   about	   any	   aspect	   of	   the	   way	   you	   have	   been	  approached	  or	  treated	  during	  the	  course	  of	  this	  study,	  the	  normal	  NHS	  complaints	  mechanism	  may	  be	  available	  to	  you.	  	  
9.	  Will	  my	  taking	  part	  in	  this	  study	  be	  kept	  confidential?	  As	  soon	  as	  tissue	  sample	  is	  taken	  from	  you,	  all	  information	  that	  identifies	  you	  will	  be	  removed	  so	  that	  you	  cannot	  be	  recognised.	  	  
10.	  What	  will	  happen	  to	  the	  results	  of	  the	  study?	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At	   the	   end	   of	   the	   study,	   the	   results	   will	   be	   written	   into	   a	   scientific	   paper	   for	  publication	  in	  a	  scientific	  journal.	  	  
11.	  Who	  is	  organising	  the	  research?	  This	   project	   is	   being	   organized	   by	   Doctors	   of	   St.	   James	   and	   Chapel	   Allerton	  Hospital	  under	  the	  supervision	  and	  support	  of	  Leeds	  University.	  	  
12.	  Who	  has	  reviewed	  this	  study?	  This	   study	   has	   been	   reviewed	   by	   the	   independent	   ethics	   committee	   called	   the	  Leeds	   (West)	   ethics	   committee.	   This	   committee	   is	   appointed	   to	   determine	   that	  research	  studies	  are	  ethical	  and	  do	  not	  impair	  the	  rights	  or	  well-­‐being	  of	  patients.	  We	  have	  received	  approval	  by	  this	  committee	  to	  be	  able	  to	  do	  this	  research	  study.	  	  
13.	  Contact	  for	  further	  information	  For	  further	  information	  on	  the	  study	  please	  contact:	  	  Professor	  D	  McGonagle,	  Telephone	  0113	  3924474.	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 Consent	  Form	  	  
Re:	  	  
Collection	  of	  joint	  mesenchymal	  stem	  cells	  (MSC)	  
	  
PI:	  Professor	  D	  McGonagle	  Please	  initial	  box	  	  1.	   I	  confirm	  that	  I	  have	  read	  and	  understand	  the	  patient	   information	  sheet	  dated	  	  	  	  	  	  	  for	   the	   above	   study.	   I	   have	   had	   an	   opportunity	   to	   consider	   the	   information,	   ask	  questions	  and	  have	  had	  these	  answered	  satisfactorily.	  	  	   	   	  2.	  I	  understand	  that	  my	  participation	  is	  voluntary	  and	  that	  I	  am	  free	  to	  withdraw	  at	   any	   time,	  without	   giving	   any	   reason,	  without	  my	  medical	   care	   or	   legal	   rights	  being	  affected.	  	  	  	  3.	  I	  understand	  that	  relevant	  sections	  of	  any	  of	  my	  medical	  notes	  will	  be	  looked	  at	  by	  responsible	   individuals	   from	  the	  NHS	  Trust,	  where	   it	   is	  relevant	   to	  my	  taking	  part	  in	  this	  research.	  I	  give	  permission	  for	  these	  individuals	  to	  have	  access	  to	  my	  records.	   	  	  	  	  4.	  I	  agree	  to	  take	  part	  in	  this	  research	  study	  	  	  	  ………..…………………………..	  Date:	  …………….Signature…………………….	  Name	  of	  patient:	  	  ……….	  …………………………..	  Date:	  …………….Signature…………………….	  Name	  of	  person	  taking	  consent	  (if	  different	  from	  researcher)	  	  ……….	  …………………………..	  Date:	  …………….Signature…………………….	  Researcher	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A Research Ethics Committee established by the Health Research Authority 
 
 
Yorkshire & The Humber - Leeds West Research Ethics Committee 
Room 001, Jarrow Business Centre 
Rolling Mill Road 
Jarrow 
Tyne and Wear 
NE32 3DT 
 
Telephone: 0191 428 3444 
  
 
 
18 February 2016 
 
Professor Dennis McGonagle 
Professor of Investigative Rheumatology 
University of Leeds 
Leeds Institute of Rheumatic and Musculoskeletal Medicine 
Chapel Allerton Hospital 
Chapeltown Road 
Leeds 
LS7 4SA  
 
 
Dear Professor McGonagle 
 
Study title: A proof-of-concept study to examine the safety and 
efficacy of a novel joint stem cell brushing method for 
endogenous mesenchymal stem cells mobilisation 
during knee joint microfracture for cartilage repair. 
REC reference: 15/YH/0512 
IRAS project ID: 180298 
 
Thank you for your letter of 12 February 2016, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Vice-Chair.  
 
We plan to publish your research summary wording for the above study on the HRA website, 
together with your contact details. Publication will be no earlier than three months from the 
date of this opinion letter.  Should you wish to provide a substitute contact point, require 
further information, or wish to make a request to postpone publication, please contact the 
REC Manager, Miss Christie Ord at nrescommittee.yorkandhumber-leedswest@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
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